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In order for recommendations to be constructed, different
experts must be brought together to review the literature
and it is only after several revision stages that a consensus
document is produced. Despite this long process, one of the
main limitations remains the lack of unequivocal studies to
enable evidence-based recommendations to be proposed.
In order to construct unambiguous recommendations it is
essential that these are based on studies examining the uti-
lity (diagnostic, prognostic, therapeutic) of echocardiogra-
phy data comparing a strategy which includes these findings
with one which does not. In general terms, medical imaging
particularly lacks this type of study [1]. In writing these
recommendations, we are aware of these limitations,
together with our inability to produce very regular updates
(because of the constant changes in medical technology and
information).
Our aim above all is to guide the practitioner by placing
particular emphasis on obtaining the parameters necessary
for a good quality investigation. These recommendations by
no means claim to be a “gold standard”: we have not
attempted here to offer statements representing what is
“right”, to say what a cardiologist is or is not entitled to do. 
This update is also designed to review the information
published in 1999 [2] on hypertension, organic valve
disease, prosthetic valves, chronic ischaemic heart disease
and acute coronary syndromes, coronary risk stratification
before non-cardiac surgery. We felt it was important to
describe and extent the initial document on the subject of
obtaining parameters during the investigation by describing
wherever possible the methodology, interpretation and uti-
lity of the parameter together with the specific problems it
raises. A review of the essential parameters to be collected
(the “minimum” data set) and optional parameters is provi-
ded in tabular form.
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HYPERTENSION
Several cohort studies have shown left ventricular hyper-
trophy (LVH) is a powerful risk factor for cardiac and cere-
brovascular events in hypertensive patients even after adjus-
ting for conventional risk factors (blood pressure value, sex,
age, smoking, diabetes, dyslipidaemia) [1, 2]. Echocardio-
graphy can be used to diagnose LVH with far greater specifi-
city and sensitivity than ECG [3]. Some risk data however
suggest that echocardiographical and ECG LVH provides an
additional predictive value [4]. 
Echocardiography remains the routine method for measu-
ring left ventricular mass (LVM) and the only one which has
been validated anatomically [5]. MRI, which is more expen-
sive, less widely available and cannot be used in routine
practice, is considered to be the most accurate method [6].
Measurement and classification technique 
for left ventricular geometry 
Echocardiographical measurement of LVM in M-mode has
been validated anatomically. It must be performed fol-
lowing precise recommendations [7], using the left paras-
ternal or, failing that, subcostal view. The use of harmonic
imaging overestimates wall thicknesses [8]. If it is not pos-
sible to align the M-mode beam correctly, thickness and
diameter measurements may be performed on a left paras-
ternal long axis image frozen in end diastole [9]. LVM is cal-
culated from the diastolic diameter and LV diastolic thic-
knesses: it is essential to calculate an average of several
measurements (minimum 2 ideally 3).
Studies on normal subjects have shown that LVM partly
depends on sex and on body shape [10]. In order to be inter-
preted, the LVM result is therefore expressed as an index
(divided) by the patient body shape index. In general, body
surface area is used although we must be aware that the
definition of the LVH threshold is still blurred illustrating
the difficulty of defining a pathological threshold for a
continuous variable: 111 g/m2 to 134 g/m2 in men and
100 g/m2 to 125 g/m2 in women depending on the publica-
tion [11]. The recent ASE recommendations [9] propose a
value of 115 g/m2 in men and 95 g/m2 in women. This
approach underestimates the prevalence of LVH in obese
people and a height indexation2,7 is recommended (hypertro-
phy threshold around 50 g/m2,7 in both sexes) [12] (table 1).
Although the measurement technique is robust the repro-
ducibility of LVM measurements is not perfect. Comparisons
of two successive investigations in the same patient (between-
test reproducibility) or reading the same M-mode tracing on
two separate occasions may result in a difference range of
60 g in the LVM calculation (standard deviation 30 g) [13]. In
other words, a change of at least 18-20% in LVM is required
to be considered to reflect a true difference: these values
can be reduced to 10 to 13% in the hands of experienced
users with good quality instruments [14].
Several studies have shown that calculating LVM alone is
inadequate and that it is useful to describe left ventricular
geometry to better stratify risk [15, 16]. Calculating certain
additional parameters (h/r or relative wall thickness defined
as the ratio of “sum of diastolic thicknesses/left ventricular
diastolic diameter”) can define four geometrical shapes [17]
of “increasing” severity according to a detailed international
classification: normal geometry (no LVH and h/r≤0.44), con-
centric remodeling (no LVH but h/r>0.44), eccentric LVH
(LVH and h/r≤0.44), and concentric LVH (LVH and h/r>0.44).
The recent ASE recommendations [9] propose a threshold of
0.42 for the h/r ratio. This classification must be used routi-
nely and shown in all reports on hypertensive patients
(table 1).
Other measurements
Measurement of the endocardial fractional shortening (eFS)
or left ventricular ejection fraction (LVEF) raises no specific
questions in terms of interpretation. In particular, a low
LVEF can reflect impaired intrinsic contractility but may
also occur secondary to raised afterload with no impair-
ment of intrinsic contractility. Calculation of end-systolic
stress (ESS) which is obtained from arterial blood pressure
and left ventricular parameters obtained in M-mode (equa-
tion 1), can identify these situations [18]. An inverse linear
relationship exists between the eFS and ESS and it is there-
fore possible in a given patient to obtain a theoretical nor-
mal value for the eFS from calculating ESS: in the presence
of a high ESS a relatively low LVEF (or eFS) value should be
interpreted as normal.
Studying the midwall fractional shortening (mFS) can also
identify unrecognised contractility disorders (equation 2)
[19, 20]. This involves identifying shortening of the myocar-
dial layers in midwall which are very rich in circumferential
fibres and which therefore contribute to circumferential
shortening (unlike the subendocardial layers which are rich
particularly in longitudinal fibres). This calculation appears
complicated but is based on routine parameters [20]
(cf. table 2). It has been shown to be of prognostic value
[21]. The inclusion of ESS is also recommended in difficult
situations, particularly when the mFS appears to be reduced.
Filling pressures are assessed from conventional parame-
ters: generally reverse transmitral flow (Em<Am) reflects nor-
mal or only slightly increased filling pressures [22]. In LVH,
however, this rule varies and this type of flow may be compa-
tible with any situation, including a large rise in left ventricu-
lar filling pressures [23]. In most situations, therefore (Em>Am
or Em<Am with LVH), other indices are required to assess fil-
ling pressures. Studies conducted in various populations have
shown that examination of the mitral annulus by pulsed tissue
Equation 1: Calculation of meridional end-systolic stress
(mESS)
mESS = (0.334 × SBP × LVIDs)/(PWTs × (1+PWTs/LVIDs)) 
in 103 dyn/cm2 
LVIDs: end-systolic left ventricular internal diameter; PWTs: end-systo-
lic posterior wall thickness; SBP: systolic blood pressure.
Equation 2: Calculation of midwall fractional shortening
(mFS)
mFS (%) = [((LVIDd+(PWTd/2)+(IVSd/2))−
((LVIDd+(IVSd/2)+(PWTd/2))3−(LVIDd3−LVIDs3))1/3)/ 
(LVIDd+(PWTd/2)+(IVSd/2))]*100 
IVSd: interventricular septum at end diastole; LVIDd: end-diastolic left 
ventricular internal diameter; LVIDs: end-systolic left ventricular inter-
nal diameter; PWTd: posterior wall thickness at end diastole.
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Doppler [24], and/or measurement of colour M-mode propa-
gation velocity [25], or even studying pulmonary venous flow
by pulsed Doppler [26] can provide a qualitative evaluation of
left ventricular filling pressures.
The initial part of the aorta must be measured at the
level of the sinus of Valsalva and at tubular level as a small
dilatation of the initial tubular aorta has been described in
hypertensives [27]; left atrial dilatation is found variably in
the literature in hypertensives [28].
Measurement of pulmonary pressures (tricuspid or pul-
monary regurgitation flow) is essential to assess the pulmo-
nary consequences of hypertensive heart disease (systolic
and/or diastolic left ventricular dysfunction). Being hyper-
tensive shifts the limit of normality for pulmonary pressures
upwards [29].
Dynamic obstruction may be seen in a hypertensive
patient with LVH, generally concentric (small cavity, thick
walls). Typically, these are patients who have become
symptomatic (dyspnea, chest pain) after vasodilators, or
fluid depletion (diuretics) [30, 31].
Utility of Doppler echocardiography 
in the hypertensive 
Measurement of LVM and assessment of left ventricular
geometry contribute to risk prediction in the hypertensive. 
Many studies have shown 1) the adverse prognostic role of
LVH [1, 2], 2) the increased risk associated with concentric
geometry in patients with LVH [32], 3) the increased risk in
patients with concentric remodelling (normal mass, increased
h/r) compared to people with a strictly normal left ventricle
[15, 16]. Doppler echocardiography may therefore form part
of the initial assessment of any hypertensive patient, particu-
larly to obtain baseline left ventricular geometry.
The presence of LVH or even concentric remodelling in
the low risk hypertensive should lead to pharmacological
treatment of the hypertension [33]. Concentric remodelling
ultimately resulting in treatment being started was found in
13% of a population of hypertensive patients left without
treatment after strict application of international recom-
mendations (particularly not taking account of echocardio-
graphy findings) [34]. 
Conversely, some studies have shown that regression of
LVH is beneficial [35], whereas progression is associated
with poor prognosis [36]. These results however do not sup-
port repeated LVM measurements in the follow-up of a
hypertensive patient as the changes in LVM in response to
treatment are usually within the limits of reproducibility of
the measurement [37]. 
Apart from assessment of cardiovascular risk Doppler
echocardiography findings are also extremely useful in the
symptomatic hypertensive patient: identification of asso-
ciated heart disease, raised left ventricular filling pressures
(Em<3 cm/s has a poor prognostic value) [38], pulmonary
arterial hypertension, left intraventricular dynamic obs-
truction on treatment, etc. 
Finally, Doppler echocardiography findings can guide
treatment in some situations: the presence of normal left
Table 1 Hypertension: obligatory parameters to be recorded.
Measurements Calculations Technical comments Value 
LVIDd, LVIDs Parasternal M-mode; 
failing that sub-costal M-mode; 
failing that parasternal 2D
LV dilated if:
LVIDd >31 mm/m2(men) LVIDd >32 mm/m2(women) 
IVSd, PWTd  Parasternal M-mode; 
failing that sub-costal M-mode; 
failing that parasternal 2D
PWTd >11 mm generally indicates LVH
(IVSd+PWTd)/
LVIDd
Eccentric if <0.42-0.44; Concentric if ≥0.42-0.44 
Prognostic value 
LV mass/m2 Penn or ASE equations Unusable in obese people Thresholds: men: 111-134 g/m2 ;
women:100-125 g/m2
Prognostic value
eFS Normal: 27-45% (if concentric geometry, eFS normal >40%)
If eFS <27%, take ESS into account in interpreting 
Aorta High parasternal for the tubular Small tubular dilatation possible in hypertensive 
Left atrium Diameter (Parasternal M-mode); 
Area (4 chambers vue); 
Volume (4 and 2 chambers vue).
No apparent dilatation (literature ambiguous)
Em, Am Pulsed Doppler, between 
annulus and tip of valve
If Em<Am and no LVH; suggests normal LV filling pressures 
For other situations, see table 2
VmaxTR Failing this, record pulmonary 
regurgitation.
SPAP threshold = 40 mmHg from 50 years old 
Am: transmitral flow A wave; ASE: American Society of Echocardiography; ESS: end-systolic stress; LVIDd: end-diastolic left ventricular 
internal diameter; LVIDs: end-systolic left ventricular internal diameter; Em: transmitral flow E wave; eFS: endocardial fractional shor-
tening; LVH: left ventricular hypertrophy; SPAP: systolic pulmonary artery pressure; PWTd: posterior wall thickness at end diastole; 
IVSd: interventricular septum at end diastole; LV: left ventricle; Vmax TR: maximum tricuspid regurgitation velocity: 2D: 2 dimensional
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ventricular geometry in mild hypertension can predict good
blood pressure control by lifestyle and dietetic measures
alone [39]. The choice of treatment for isolated LVH and/or
left ventricular dilatation will be different.
Recommendations from 
the learned societies
The main published recommendations on the management of
hypertension (HT) are still vague about the role of echocar-
diography. This lack of detail may be explained by 1) the
absence of pragmatic studies comparing management strate-
gies which do or do not incorporate echocardiography fin-
dings and 2) the financial implications if the investigation
were to become used systematically, even in targeted cases.
The American findings from the Joint National Committee
[40] recall the need to identify target organ damage and the
possibility of using clinical and laboratory findings and other
tests to do this… although no further details are given.
European recommendations [33] are more precise and
stress the role of possible LVH in assessing overall cardio-
vascular risk: they suggest up to 50% of hypertensives may
be underestimated, being considered to be at low or mode-
rate risk after a standard assessment becoming high risk
when echocardiography or carotid findings are incorpora-
ted. These tests are therefore recommended particularly
when a decision is being taken not to treat or doubt about
the need to treat exists [34].
The British Hypertension Society [41] states that echo-
cardiography is one of the assessment tools without giving
any specific guidance. The recommendations stress the role
of target organ damage, for example, in guiding the deci-
sion to treat mild hypertension (SBP 140-159 mmHg and/or
DBP 90-99 mmHg).
Echocardiography is not recommended routinely in all
patients in the Canadian recommendations [42] and must
not be used to investigate for regression of LVH on treat-
ment. These minimalist recommendations appear however
to have been very widely disputed and because of the
increasing amount of data showing the prognostic role of
LVH, the next recommendations should provide more speci-
fic details about the place of echocardiography.
The French Higher Health Authority [43] stresses the
role of target organ damage (LVH), requiring drug treat-
ment for SBP of 140-179 mmHg or DBP 90-109 mmHg.
Echocardiography is not however recommended systema-
tically but can be performed in specific situations. The
real place of echocardiography in the initial assessment
will need to be described in the future, particularly from
medico-economic studies.
All the recommendations therefore stress the prognostic
value of LVH and its consequences in terms of manage-
ment…, but very few take the further step of clearly descri-
bing the place of echocardiography. 
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Table 2 Hypertension: optional parameters to be recorded.
Measurements Calculations Technical comments Value
SBP During the investigation 
(automatic measurement)
PWTs
LV mass/height2,7 Height in “meters” Prognostic value 
Thresholds 51 g/m2,7 
Suitable in both sexes and in all body types (obese ++) 
mFS Calculated from the LVIDd, 
LVIDs, IVSd, PWTd
Normal values 15-23%
Prognostic value
 End systolic stress Requires SBP, PWTs, LVIDs Aid to interpreting eFS <27%
Aid to interpreting mFS <15%
Ea Septal and lateral site Prognostic value
Vp Color M-mode 
Ap duration Pulsed Doppler 
Em/Ea
Em/Vp
Duration (Ap-Am)
Necessary to assess LV 
filling pressures
When Em>Am
When Em<Am and LVH
Filling pressure is raised if:
Em/Ea>15
Em/Vp>2
Duration (Ap – Am) >20ms 
Testing for 
coarctation
Continuous wave Doppler, 
suprasternal
 
LV outflow tract 
obstruction 
Continuous wave Doppler, 
apex
Consider in patients who have become
symptomatic on treatment
Am: transmitral flow A wave; Ap: pulmonary venous flow A wave; Em: transmitral flow E wave; Ea: pulsed tissue Doppler E wave at the 
mitral annulus; eFS: endocardial fractional shortening; IVSd: interventricular septum at end diastole; LVIDd: end-diastolic left ventri-
cular internal diameter; LVIDs: end-systolic left ventricular internal diameter; mFS: midwall fractional shortening; LVH: left ventricular 
hypertrophy; PWTd: posterior wall thickness at end diastole; PWTs: end-systolic posterior wall thickness; SBP: systolic blood pressure; 
Vp: color M-mode flow propagation velocity.
Consensus indications for Doppler-echocardiography in
the initial assessment of a hypertensive patient 
Class I
— Transthoracic Doppler echocardiography in the initial 
assessment of repercussions of hypertension associated 
with known or suspected heart disease. 
— Transthoracic Doppler echocardiography in the initial 
assessment of repercussions of hypertension associated 
with unexplained cardiac symptoms. 
— Transthoracic Doppler echocardiography in the initial 
assessment of repercussions of hypertension associated 
with severe hypertension (high risk) even if the ECG is 
normal. 
— Transthoracic Doppler echocardiography in the initial 
assessment of an ECG abnormality: LVH, LBBB, repolari-
sation disorders.
Class II 
Transthoracic Doppler echocardiography in the initial 
assessment of repercussions of hypertension particularly 
if the results may alter management (for example low or 
medium risk level, guiding a decision not to treat).
Class III 
Transoesophageal echocardiography or stress echocar-
diography assessment of uncomplicated hypertension. 
Consensus indications for transthoracic Doppler echocar-
diography in the follow-up of a hypertensive patient 
Class I
— Annual follow-up of treated hypertension with systolic 
left ventricular dysfunction on initial Doppler echo-
cardiography. 
— Follow-up of left ventricular function every 2 to 
3 years in treated hypertension associated with LVH on 
initial Doppler echocardiography. 
— Evaluation of treatment-resistant hypertension even 
with a normal ECG. 
Class II 
2 to 3 years follow-up of treated hypertension associated 
with left ventricular diastolic dysfunction on initial 
Doppler echocardiography. 
Class III 
Evaluation of regression of LVH on treatment.
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ORGANIC VALVE DISEASES
Introduction
Doppler echocardiography has become the reference
method to describe valvular anatomy, establish the diagno-
sis of dysfunction and quantify precisely the mechanism
responsible for dysfunction by assessing the repercussions
on dimensions and function of the cardiac cavities and to
assess the resultant haemodynamic disturbances.
Quantification relies on the coherence of a number of para-
meters which when taken in isolation may be a source of
error. Assessment of regurgitation which is traditionally more
difficult than stenosis, has benefited from the use of the
proximal isovelocity surface area method (PISA). 
All the quantification methods, including assessment of a
stenosed orifice by the surgeon (which does not strictly
represent the functional in vivo orifice) have sources of
error, particularly in certain situations highlighting the
importance of comparing echocardiography results with cli-
nical findings; and in difficult cases (asymptomatic patients,
inconsistency between symptoms and the resting assess-
ment, low output etc.) it is useful to perform a dynamic test
(pharmacological or usually physical exercise). 
The indications for transoesophageal echocardiography
(TOE) have reduced in parallel to improvement in transtho-
racic imaging and are now reserved for well defined, speci-
fic situations. 
Finally, a range of investigations (coronary artery CT
scan or coronary angiography in particular), are still neces-
sary in a large number of patients prior to surgery.
Assessment of valve diseases: 
Methods of measurement
Orifice stenoses
Doppler echocardiography can be used to diagnose valvular
stenosis, to describe the extent of cusp damage (fibrosis,
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calcification), to assess the restriction (tethering?) of the
valve apparatus and to assess left ventricular function.
Aetiology and mechanism
Examination of the aortic valve is designed to assess the
level of valve calcification and to identify a bicuspid valve.
The diagnosis of a bicuspid aortic valve, although difficult
in diastole in the presence of a raphe or valve calcifications
is based on demonstrating 2 asymmetrical sigmoid cusps in
a short axis parasternal view.
Examination of the mitral valve must be exhaustive in
order to guide any possible therapeutic procedure. Diffe-
rent scores have been proposed, incorporating cusp thic-
kness and mobility, presence of calcifications, commissu-
ral areas and thickening of the subvalvular apparatus. In
particular, the importance of valvular calcifications and
the state of the subvalvular apparatus are anatomical fac-
tors that predict the success of percutaneous commissu-
rotomy.
Quantification
The quantification methods depend partly on the studied
orifice (tables 1-4):.Regardless of valve orifice, Doppler measurement of the
mean transvalvular pressure gradient correlates well
with the mean gradient found on catheterisation when
the measurements are performed simultaneously [1, 2].
It is always important to correctly align the transvalvular
flow and the ultrasound beam as a significant angle
between these two is liable to lead to gross under-esti-
mation of velocity and pressure gradient. This is a critical
point particularly for aortic stenoses — placing the probe
in different positions minimizes the angle between the
jet and the ultrasound beam. An adequate Doppler signal
is generally obtained from the apical position. However,
in some patients, despite an apical Doppler envelope of
acceptable quality, higher velocities may be are recor-
ded in the right parasternal or even suprasternal or
xiphoid views..Measurement of the functional surface area by the conti-
nuity equation is reliable for both mitral and aortic orifi-
ces [3, 4]. To optimise indications for treatment, parti-
cularly for the aortic orifice, body surface area needs to
be taken into account. This method requires coupling of
two-dimensional echocardiography and both Doppler
modes (pulsed and continuous). Apart from technical
problems related to errors in measuring the diameter of
the left ventricular outflow tract or incorrect positioning
of the pulsed Doppler sample, the method may be inap-
propriate in the presence of an accelerated flow in the
outflow tract, as well as in patients with mitral regurgi-
tation or atrial fibrillation with rapid ventricular res-
ponse. Although estimating valve surface area is less
dependent on haemodynamic conditions than estimation
of the gradient, some authors dispute its validity in
patients with low cardiac output [4 bis]. The measure-
ment of the radius of the Doppler colour convergence
zone [5] in 2D or TM mode, has been recently proposed
for the mitral orifice as alternative to the continuity
principle. However, this method is not frequently used in
routine practice..Measurement of the time required for the pressure across
the mitral valve during diastole to fall to one-half of its
initial value (pressure half time) can be use for the quan-
tification of mitral stenosis [6]. This is straightforward to
perform although its interpretation must take into
account technical causes of error (slope too short or non-
linear, atrial arrhythmias, etc.) and factors not related
to the mitral obstruction, primarily the features of left
ventricular filling or left atrial emptying. Concomitant
aortic regurgitation can also influence results..Direct measurement of the surface area of the stenosed
orifice by planimetry in two- or even three-dimensional
echocardiography is considered by many authors to be
the reference quantification method for mitral stenoses
[7]. It can also be used in selected cases for aortic steno-
ses, especially in multiplane transoesophageal echocar-
diography. Reliability depends on operator experience,
quality of instrument, observation conditions and ability
to determine the outline of the stenosed orifice (pro-
blems with irregular orifices and particularly with exten-
sive calcification etc.)..Other quantification indices (valve resistance, etc.) have
not been shown to be superior to the calculation of sur-
face area and are not used routinely.
Table 1 Aortic stenosis: obligatory parameters to record.
Parameters Threshold Comments Value
Maximal aortic velocity Severe AS >4 m/s Asymptomatic patients Prognostic value
Mean LV-Aorta gradient 
(rest)
Severe AS: >40 mmHg (ACC/
AHA)
Severe AS: >50 mmHg (ESC; SFC )
Several views 
(right parasternal ++)
Depends on output. 
Risk of underestimation if 
all views are not analyzed.
Aortic surface area 
continuity equation 
Severe AS <1 cm2 
(ACC/AHA, ESC)
Severe AS <0.5 cm2/m2 BSA (SFC)
Severe AS <0.6 cm2/m2 BSA
(ACC/AHA, ESC)
BSA indexation debatable: of 
use for extreme body mor-
photypes 
Less dependent on output. 
Invalid in outflow tract 
obstruction 
AS: aortic stenosis; BSA: body surface area; LV: left ventricle
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Table 2 Aortic stenosis: optional parameters.
Parameters Threshold Comments Value 
Exercise  Mean gradient >18 mmHg Asymptomatic patients Prognostic value to be 
confirmed (only 1 study) 
Low dose dobutamine Mean gradient >30 mmHg
Surface area <1.2 cm2
Patients with calcified 
valve, LVEF <40% and 
mean basal gradient 
LV- aorta <30 mmHg
Diagnostic and prognostic 
value
Surface area by planimetry Severe AS <1 cm2 (ACC/AHA, ESC)
Severe AS <0.5 cm2/m2 BSA 
(SFC)
Severe AS <0.6 cm2/m2 BSA 
(ACC/AHA, ESC)
Transthoracic or 
transoesophageal view
Limited to moderately 
calcified orifices when 
continuity equation invalid
Patency index Severe AS <25% Simple Relatively non-specific 
Valve resistance Severe AS >300 dynes.s.cm-5 Poor
LVEF: left ventricular ejection fraction; AS: aortic stenosis; BSA: body surface area; LV: left ventricle
Table 3 Mitral stenosis: obligatory parameters to record.
Parameters Threshold Comment Value
Mean LA-LV gradient 
(mmHg) (rest)
Moderate MS: 
<5 mmHg
Severe MS: 
>10 mmHg
Calculate mean measurements
(AF ++) 
Mediocre when performed alone 
(depends on output)
2D surface area Severe MS <1.5 cm2 
(<1 cm2/m2 BSA)
Measure the smaller orifice
(funnel tip) 
Anatomical surface area 
Gold standard
PHT surface area Severe MS <1.5 cm2 
(<1 cm2/m2 BSA)
Easy, quick Poor when performed alone 
Multiple causes of error
2D: two-dimensional; AF: atrial fibrillation; LA: left atrium; PHT: pressure half time; MS: mitral stenosis; LV: left ventricle
[the mean mitral gradient is only an argument supporting the degree of stenosis but cannot be a unique quantification factor]
Table 4 Mitral stenosis: optional parameters to record.
Parameters Threshold Comment Value
Mean LA-LV gradient on 
exercise
>15 mmHg Difficult if rapid heart rate Useful when basal evaluation difficult. 
Threshold value poorly documented 
prognostically
Systolic PAP on exercise >60 mmHg Threshold value poorly documented 
prognostically 
Continuity surface area Severe MS <1.5 cm2 
(<1 cm2/m2 BSA)
Pulmonary view rarely used 
Functional surface 
< anatomical surface area
Many causes of error 
3D surface area Severe MS <1.5 cm2
(<1 cm2/m2 BSA)
Appears to be more 
reproducible than 2D with 
inexperienced observers
Same limitations as 2D (echogenicity)
Specific equipment
PISA method (M-mode 
or 2D)
Severe MS <1.5 cm2 
(<1 cm2/m2 BSA)
Angle generally between 
100° and 130° 
Precise angle determination aleatory
PAP: pulmonary artery pressure; 2D: two-dimensional; 3D: three-dimensional; LA: left atrium; MS: mitral stenosis; LV: left ventricle
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Valve regurgitation
Doppler echocardiography provides a positive diagnosis of
valve regurgitation regardless of site, with a sensitivity and
specificity of close to 100%. It describes the aetiology,
mechanism [8] and severity of valve regurgitation [9].
Aetiology and mechanism
As regard to the aortic valve, echocardiography provides
morphological information on the number of valves and
valve texture, describes the size of the aortic annulus and
detects lesions susceptible to change the surgical strategy
or complicate surgery (dilatation of the ascending aorta,
annulus calcifications extending towards the aorto-mitral
trigone etc.).
At the mitral level, the functional classification proposed
by Carpentier is widely used: (type 1: normal valve move-
ments; type 2: valve prolapse; type 3: restricted valve
movements). In patients with prolapse, a segmental analy-
sis must also be performed. This analysis provides informa-
tion on the 8 segments of the mitral valve: 2 commissures,
3 segments for the posterior valve (P1, P2, P3) and 3 for the
anterior valve (A1, A2, A3). The use of such common classi-
fications improves the collaboration between cardiologist
and surgeon and clarifies the indications for treatment as
regard to the type of surgery considered, i.e. mitral valvu-
loplasty or valve replacement.
 At a tricuspid level, Doppler echocardiography can
detect large functional regurgitations with repercussion on
the right cavities which can be surgically resolved simulta-
neously with left heart lesions. It also describes the mecha-
nisms of rare organic valve damage (table 5).
Quantification
As for stenoses, quantification of regurgitations [9] is based
on a comparison of all the direct and indirect criteria [10-15]
reviewed below (tables 6-11). Indirect criteria are represen-
ted by the consequences of the regurgitation on the cardiac
cavities reflecting both the importance of the regurgitated
volume and the chronicity of the valvular lesion, but also by
haemodynamic repercussions (left ventricular filling pressu-
res, pulmonary artery pressure) The mechanism of the regur-
gitation is sometimes helpful for quantifying the severity
(severe valve damage, ruptures of the mitral valve papillary
muscle or cordae, and aortic sigmoid eversion are generally
associated with major regurgitations). Direct criteria are
recorded by Doppler. The study of the jet extension by
colour Doppler is a source of errors and has now become
obsolete. Semi-quantitative and quantitative methods are
widely used. Examining the proximal isovelocity surface area
offers major advantages as it provides an estimation of the
effective regurgitant orifice and the regurgitated volume
(speed, simplicity, validity in the presence of associated
valve disease or arrhythmias). However, methodological
limitations (particularly interaction with adjacent structu-
res) must not be underestimated. Overall, the number and
complementarity of available indices make ultrasound the
reference quantification method in routine practice. 
In clinical practice, the investigation always begins with
two-dimensional echocardiography which can suggest from
the outset severe regurgitation in the presence of a major
defect of valve closure or conversely, minor regurgitation
when the valve anatomy is normal. This is followed by a
careful assessment of the regurgitant jet by colour Doppler,
increasing the section planes. This allows a rapid diagnosis
of minimal regurgitation. Further quantification is gene-
rally not needed in these minimal regurgitations. In other
cases a quantitative methods are required. Analysis of the
proximal isovelocity surface area is the preferred method.
Results are then compared with semi-quantitative parame-
ters. The repercussion on the cardiac cavities and pulmo-
nary artery pressure are examined. In difficult cases tran-
soesophageal echocardiography is performed although
transthoracic approach is usually sufficient. 
Table 5 Doppler parameters used to quantify tricuspid regurgitation: threshold values.
Parameters Mild tricuspid regurgitation Severe tricuspid regurgitation 
Semi-quantitative
. vena contracta diameter
. systolic reversal of SHVF
 
absent
>7 mm
present
Quantitative
. effective regurgitant orifice area incompetence <20 mm2 >40 mm2
SHVF: suprahepatic venous flow
Table 6 Aortic regurgitation: obligatory parameters to record.
Parameters Comment Value
Pressure half Time Apical view usually
Right parasternal view (Pedoff) 
in some cases of prolapse 
Reflects LVEDP: 
Poor specificity for regurgitant volume 
Index of haemodynamic tolerance
Isthmus speed Minimum wall filter Good in adults 
VC Diameter TTE or TOE Good for central jets 
ERO and RV (PISA) Apical or parasternal view 
(prolapse ++)
Inferior compared with mitral regurgitation  (technical 
difficulties for radius determination).
+ Systematic left ventricular diameters
ERO: effective regurgitant orifice area; PISA: proximal isovelocity surface area; LVEDP: left ventricular end-diastolic pressure; 
SRO: surface area of regurgitant orifice; VC: vena contracta; RV: regurgitant volume
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Table 7 Aortic regurgitation: optional parameters to record.
Parameters Comment
Regurgitant fraction Long, tedious
Causes of error (mitral flow rate ++)
Aortic output Limited in LV dysfunction LV, AF…
AF: atrial fibrillation; LV: left ventricular
Table 8 Doppler parameters used to quantify aortic regurgitation: threshold values.
Parameters Moderate aortic regurgitation Severe aortic regurgitation 
Semi-quantitative 
. vena contracta diameter 
. aortic isthmus end-diastolic velocity 
. aortic output 
. pressure half time
<3 mm
absent or <10 cm/s
<6 L/min
>500 ms
>6 mm
>20 cm/s
>10 L/min
<300 ms
Quantitative
. effective regurgitant orifice area
. regurgitated volume/beat 
. regurgitation fraction 
<10 mm2
<30 ml
<30%
>30 mm2
>60 ml
>50%
Table 9 Mitral regurgitation: obligatory parameters to record.
Parameters Comment Value
ERO and RV (PISA) Limits: 
Multiple jets (Barlow)
Confined jets (commissural prolapse)
Current gold standard 
Probably overestimates regurgitations in MV 
prolapse 
Independent of load conditions 
Vena contracta diameter Preferably left parasternal view 
Use of zoom
limitations (echogenicity, multiple jets, 
eccentric jets)
+ indirect criteria systematically (cardiac cavities, pulmonary pressures, etc.) 
ERO: effective regurgitant orifice area; PISA: proximal isovelocity surface area; RV: regurgitated volume.
Table 10 Mitral regurgitation: optional parameters to record.
Parameters Comment Value
Regurgitant fraction Volume ejected at aortic annulus 
Total volume in 2D echo (Simpson)
Longer and more complex than PISA
Useful when PISA invalid or equivocal
Mitral VTI/Aortic VTI Simpler than calculating regurgitation fraction Limitations (associated valve disease, atrial 
fibrillation…)
VTI: velocity time integral; PISA: proximal isovelocity surface area
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Follow-up of organic left heart valve disease:
transthoracic Doppler echocardiography
The surgical indications, which largely depend on the echo-
cardiographical findings, are described in the recently
published recommendations from the valve group of the
Société Française de Cardiologie (SFC) [16], the European
Society of Cardiology (ESC) [17], and the American Heart Asso-
ciation/American College of Cardiology (AHA/ACC) [17 bis].
Aortic valve diseases
Moderate valve disease with no repercussions on the car-
diac cavities or left ventricular function, which do not pro-
duce symptoms and are clinically stable do not require
close regular monitoring. In other cases the methods and
frequency of Doppler echocardiography monitoring depend
on the valve disease in question.
Aortic stenosis
The natural history of degenerative aortic stenosis is relati-
vely well known: the aortic surface area has been shown to
fall by an average of 0.1 to 0.2 cm2 per year, although
considerable inter-individual differences exist. Asymptomatic
aortic stenosis has a good prognosis with a very low risk of sud-
den death [17, 18]. Different predictors of poor outcome in
asymptomatic patients have been identified: a peak aortic jet
velocity >4m/s, rapid increase in velocity >0.3 m/s per year,
the presence of extensive valve calcifications and finally an
abnormal response to exercise testing [16-19]. There are few
data suggesting the prognostic value of exercise echocardio-
graphy and its precise role remains to be established. The pro-
gnostic value of severe left ventricular hypertrophy (wall thic-
kness >15 mm) or a very high mean gradient (>75 mmHg) is
still subject of debate. Echocardiography has become the
standard method for assessing the severity of aortic stenosis.
The two main criteria in favor of severe aortic stenosis are a
mean gradient >50 mmHg, and an aortic valve area <1 cm2 (or
indexed aortic valve area <0.6 or 0.5 cm2/m2 in patients with
either unusually small or large body surface areas). It should
be emphasized that all of these measurements have potential
inaccuracies and must be considered in combination with flow
rate, ventricular function and functional status for clinical
decision making [16]. Annual Doppler echocardiography helps
to distinguish rapid progressors (reduction in aortic surface
area of more than 0.1 cm2/year) from patients in whom the
stenosis progresses slowly (reduction in aortic surface area of
less than 0.1 cm2/year). It is also used to monitor patients
with well tolerated severe aortic stenosis.
Aortic regurgitation
The indication for surgery in patients with severe aortic
regurgitation is undisputed clear in the presence of
symptoms due to the regurgitated volume and its haemo-
dynamic repercussions [16, 17]. The risks of surgery and
of prosthetic valve complications in asymptomatic
Table 11 Doppler parameters used to quantify organic, non-ischaemic mitral regurgitation: threshold values.
Parameters Mild mitral regurgitation Severe mitral regurgitation
Semi-quantitative
. vena contracta diameter
. Mitral VTI/Aortic VTI
. Pan- or mid-systolic reversal of PVF 
<3 mm
<1
absent
>7 mm
>1.4
present
Quantitative
. effective regurgitant orifice area
. regurgitant volume/beat
. regurgitation fraction
<20 mm2
<30 ml
<30%
>40 mm2
>60 ml
>50%
VTI: velocity time integral; PVF: pulmonary venous flow.
Indications for transthoracic Doppler echocardiography
in aortic stenosis
Classe I
— Initial work-up for clinically diagnosed aortic stenosis.
— Investigation of functional signs that might be due to 
aortic stenosis if the physical examination was not infor-
mative.
— Changes in functional signs or physical examination 
findings in a patient with known aortic stenosis.
— Annual or twice-yearly re-assessment of asymptoma-
tic, severe aortic stenosis.
— Annual re-assessment of moderate aortic stenosis with 
impaired left ventricular systolic function caused by 
some other aetiology.
— Twelve-month re-assessment of asymptomatic aortic 
stenosis initially judged as moderate. Later, annual 
check-ups in the event of rapid deterioration; every two 
or three years if deterioration is slower.
— Re-assessment of moderate-to-severe aortic stenosis 
before intermediate-to-high risk extracardiac surgery 
(see page 284) or before cardiovascular surgery if the 
last Doppler echocardiography was performed more than 
one year previously.
Classe II
— Re-assessment of moderate-to-severe aortic stenosis 
before intermediate-to-high risk extracardiac surgery 
(see page 284) or before cardiovascular surgery if the 
last Doppler echocardiography was performed less than 
one year previously.
Classe III
— Annual re-assessment of clinically stable, mild or 
slowly-deteriorating, asymptomatic aortic stenosis, 
without any significant impact on the heart cavities 
according to the initial examination.
260 E. Abergel et al.
patients must be balanced against those due to the natu-
ral progression of the valve disease. It has been shown
that symptoms and/or left ventricular dysfunction deve-
lop at an annual rate of approximately 4% in asymptoma-
tic patients with aortic regurgitation [20]. Left ventricu-
lar dilatation (left ventricular end-diastolic diameter >70
mm and in particular, left ventricular end-systolic diameter
>50 mm or >25 mm/m2) and/or reduction in LV ejection
fraction (<50%) represent arguments for surgery in the
presence of severe aortic regurgitation [21]. Changes in
left ventricular function parameters have also a prognos-
tic role [20, 21] and some authors have proposed bian-
nual follow-up in patients with left ventricular end-systo-
lic diameters between 50 and 55 mm [20]. 
The natural history of aortic root aneurysm has been
mainly evaluated mostly in patients with Marfan’s syn-
drome or bicuspid aortic valve. The main predictive fac-
tors of aortic complications are the aortic diameter, the
rate of progression of aortic dilatation and a family history
of sudden death or aortic complication.
Mitral valve diseases
Mitral valve diseases must be investigated by Doppler echo-
cardiography in order to assess anatomical changes, seve-
rity, left ventricular repercussions (in mitral regurgitation)
and pulmonary pressures [9, 16].
Mitral stenosis 
Mitral stenosis is considered to be tight if the surface area
of the mitral valve is less than 1.5 cm2 (or 1 cm2/m2 body
surface area). 
Mitral stenosis usually progresses slowly, with a long asymp-
tomatic period. Progression of mitral stenosis is assessed by
measuring the mitral valve surface area and the variation of
the other parameters (gradient/pulmonary artery pressure/
left atrial diameter).
Percutaneous mitral dilatation
Baseline Doppler echocardiography must be performed
after percutaneous mitral dilatation, preferably under sta-
ble haemodynamic conditions, i.e. more than 48 hours after
the procedure. The frequency of subsequent investigations
is governed by the quality of the initial result.
Organic mitral regurgitation
The indication for surgery in patients with severe mitral
regurgitation is clear in the presence of symptoms due to the
regurgitated volume and its haemodynamic repercussions.
The approach varies in asymptomatic patients. The develop-
ment of left ventricular repercussions (left ventricular end-
systolic diameter of 45 mm or more, left ventricular ejection
fraction <60%) represents an indication for surgery. In asymp-
tomatic low-risk patients with severe regurgitation (regurgi-
tant orifice >40mm2 and/or regurgitated volume >60 ml/
Consensus indications for transthoracic Doppler echo-
cardiography in aortic regurgitation
Class I
— Initial assessment of clinically diagnosed aortic regur-
gitation.
— Changes in symptoms or clinical examination in 
patients previously diagnosed with known aortic regurgi-
tation.
— Annual or bi-annual (if rapid progression) evaluation of 
ascending aorta if >45 mm, in patients with aortic root 
aneurysm and bicuspid aortic valve
— Annual or bi-annual (according to severity and evolu-
tivity of left ventricular involvment) evaluation of 
severe asymptomatic aortic regurgitation medically fol-
lowed.
— Evaluation of a known moderate to severe AR before 
intermediate or high-risk extracardiac surgery (see page 
284) if the last Doppler echocardiography was performed 
more than one year previously.
— Reference examination within 3 months after aortic 
valve conservative surgery or Ross procedure.
Class II
— Annual assessment of moderately severe aortic regur-
gitation.
— Evaluation of a known moderate to severe AR before 
intermediate or high-risk extracardiac surgery (see page 
284) if the last Doppler echocardiography was performed 
less than one year previously.
Class III
— Annual re-assessment of minor aortic regurgitation 
with no left ventricular repercussions and stable clinical 
parameters.
Consensus indications for transthoracic Doppler echo-
cardiography in mitral stenosis
Class I
— Initial assessment of clinically diagnosed or suspected 
mitral stenosis.
— Changes in symptoms or clinical examination in patients 
with known mitral stenosis.
— Assessment of complications during evolution of mitral 
stenosis.
— Systematic reassessment of mitral stenosis, with a fre-
quency depending on the results of the initial evalua-
tion: yearly in severe mitral stenosis to several year 
intervals in moderate mitral stenosis
— Initial reassessment (first month) of mitral stenosis 
treated by percutaneous mitral commissurotomy (the 
frequency of subsequent follow-up is determined by the 
quality of the initial result).
— Re-assessment of moderately severe to severe mitral 
stenosis before intermediate or high risk extra-cardiac 
surgery (see page 284) or before cardiovascular surgery 
if the last Doppler echocardiography was performed 
more than one year previously.
Class II
— Re-assessment of moderately severe to severe mitral 
stenosis before intermediate or high risk extra-cardiac 
surgery (see page 284) or before cardiovascular surgery 
if the last Doppler echocardiography was performed less 
than one year previously.
Class III
— Annual re-assessment of clinically stable, non-tight 
mitral stenosis.
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beat) and favourable mitral anatomy, the current trend is to
operate early and perform valvuloplasty in order to preserve
left ventricular function and avoid left atrial dilatation [22].
If uncertainty about the feasibility of valvuloplasty exists, or
in the presence of co-morbidities regular follow-up is appro-
priate. Surgery becomes the rational choice at the occur-
rence of symptoms, left ventricular dysfunction, pulmonary
arterial hypertension or atrial fibrillation [22 bis]. In patients
with severe mitral regurgitation managed medically the main
risk is related to the insidious development of LV dysfunc-
tion. This justifies annual or bi-annual follow-up depending
on the initial findings.
Follow-up left heart valve
diseases: transoesophageal echocardiography 
.Transoesophageal echocardiography is particularly useful
for the diagnosis of complications of known valve disease.
Occasionally it helps determining the operative strategy in
patients in whom surgery is indicated. Transoesophageal
echocardiography is recommended in patients with a his-
tory of embolic events or in those in whom left atrial
thrombosis has to be excluded before cardioversion or
percutaneous mitral dilatation. The close relationship
between the oesophagus and the left atrium [23] and the
poor sensitivity of transthoracic echocardiography to
detect left atrial thromboses make transoesophageal
echocardiography a valuable procedure for assessing car-
diac thrombosis. Transoesophageal echocardiography is
also frequently used in patients with suspected endocardi-
tis, aortic wall complications or as an adjunct for exami-
ning the ascending aorta, particularly in bicuspid aortic
valve before surgery. Patients with severe mitral regurgi-
tation in whom the feasibility of conservative surgery
remains unclear after transthoracic echocardiography may
also benefit from the transesophageal approach. 
In aortic stenosis, the technique may be used for the
planimetry of the aortic orifice [24] in a minority of
patients in whom the transthoracic Doppler echocardiogra-
phy quantification provided inconsistent results (poor
observation conditions, flow acceleration in the outflow
tract etc.) and occasionally in selected patients with athe-
roma of the aortic arch at risk of complications at cathete-
risation or cardiac surgery. Transoesophageal echocardio-
graphy must be avoided in highly symptomatic tight aortic
stenosis. The preferred indications for transoesophageal
echocardiography in aortic regurgitation are suspected
endocarditis and suspected aortic wall complication, parti-
cularly in dystrophic aortic regurgitation. The method is
also recommended for the assessment of the regurgitation
mechanism when transthoracic observation conditions do
not permit definitive conclusions. 
Follow-up of organic left heart valve diseases:
transoesophageal echocardiography 
Several publications analyze the haemodynamic behaviour of
different left heart valve diseases during pharmacological or
physical stress [25-27]. In general terms, Doppler stress echo-
Consensus indications for transthoracic Doppler echo-
cardiography in organic mitral regurgitation
Class I
— Initial assessment of clinically diagnosed or suspected 
mitral regurgitation.
— Change in symptoms or clinical examination in 
patients with previously diagnosed mitral regurgi-
tation.
— Bi-annual or annual follow-up (depending on the seve-
rity and progression of the repercussions on left ventri-
cular function, left atrium and pulmonary artery 
pressure) for severe asymptomatic mitral regurgitation
— Baseline assessment during the 3 months following 
mitral valvuloplasty.
— Re-assessment of severe or moderately severe mitral 
regurgitation before intermediate or high risk extra-
cardiac surgery (see page 284) or before cardiovascular 
surgery if the last Doppler echocardiography was perfor-
med more than one year previously.
Class II
— Annual assessment of moderately severe mitral regur-
gitation without repercussions on cavities or left ventri-
cular function on the initial investigation with clinically 
stable parameters.
— Re-assessment of severe or moderately severe mitral 
regurgitation before intermediate or high risk extra-car-
diac surgery (see page 284) or before cardiovascular sur-
gery if the last Doppler echocardiography was less than 
one year previously. 
— Re-assessment of minor mitral regurgitation with val-
vular abnormalities and no repercussions on the cavities 
or left ventricular function on the initial examination, 
with stable clinical parameters, every 4 to 5 years.
Class III
— Annual re-assessment of moderate mitral regurgitation 
with no repercussions on the cavities or left ventricular 
function on the initial assessment, with stable clinical 
parameters.
Consensus indications for transoesophageal echocardio-
graphy in mitral stenosis
Class I
— Severe mitral stenosis when percutaneous dilatation is 
being considered (minimising the time between TOE and 
dilatation).
— Mitral stenosis complicated by an embolic event.
— Atrial dysrhythmias when cardioversion is being consi-
dered in a non-anticoagulated or poorly anticoagulated 
patient.
Class II
— Before intermediate or high risk extra-cardiac surgery 
(see page 284) or major cardiovascular surgery. 
— Atrial dysrhythmias when cardioversion is being consi-
dered in a well anticoagulated patient.
Class III
— Annual re-assessment of a mild mitral stenosis.
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cardiography can provide additional information to the base-
line assessment of valve diseases and refines indications for
treatment, particularly in asymptomatic patients or if symp-
toms are inconsistent with the baseline assessment. This
investigation is particularly useful when the “dynamic” nature
of the valve disease needs to be demonstrated (for example,
functional mitral regurgitation in heart failure). One specific
situation is aortic stenosis with severe left ventricular systolic
dysfunction associated with low output and a small gradient
(<30 mmHg). The haemodynamic response to dobutamine has
diagnostic value distinguishing significant stenoses from
moderate stenoses associated with independent left ventricu-
lar dysfunction but also prognostic value(assessment of the LV
contractile reserve) [26, 27].
Infective endocarditis
In infective endocarditis, an early diagnosis is essential.
Doppler echocardiography is currently the investigation
with the best performance in visualising vegetations and/or
assess valve dysfunction due to the endocarditis.
Consensus indications for transoesophageal echocardio-
graphy in organic mitral regurgitation
Class I
— Mechanism and quantification of mitral regurgitation 
inadequately assessed by transthoracic Doppler echocar-
diography.
— Mechanism and quantification of mitral regurgitation 
when transthoracic Doppler echocardiography and clini-
cal assessment produce inconsistent results.
— Development of a clinical event (suspected endocardi-
tis, embolic event, etc.). 
— Atrial dysrhythmias when cardioversion is being consi-
dered in a non-anticoagulated or poorly anticoagulated 
patient.
— Per-operative assessment of mitral regurgitation in 
mitral valvuloplasty.
Class II 
— Assessment of incompetent mitral valve before surgi-
cal correction.
— Assessment of the mechanism of moderate mitral 
regurgitation.
— Atrial dysrhythmias when cardioversion is being consi-
dered in a well anticoagulated patient.
Class III
— Moderate mitral regurgitation with no symptoms or 
repercussion on the cavities or left ventricular function 
on transthoracic Doppler echocardiography.
Consensus indications for transoesophageal echocardio-
graphy in aortic stenosis
Class I
— Suspected or overt infective endocarditis.
Class II
— Technical inability to correctly assess the severity 
extent of aortic stenosis by transthoracic Doppler echo-
cardiography.
— Investigation for associated lesions (thoracic aorta, other 
valve lesions, etc.) before aortic valve replacement.
Class III
— Initial assessment of aortic stenosis that was comple-
tely assessed by transthoracic Doppler echocardiography.
Consensus indications for transoesophageal echocardio-
graphy in aortic regurgitation
Class I
— Suspected aortic dissection in the presence of a dila-
ted and / or dystrophic aorta.
— Suspected or overt infective endocarditis.
— Mechanism and quantification of aortic regurgitation 
inadequately assessed by transthoracic Doppler echocar-
diography.
— Mechanism and quantification of aortic regurgitation 
when transthoracic Doppler echocardiography and clini-
cal assessment produce inconsistent results.
— Pre-operative assessment of annuloaortic ectasia when 
transthoracic Doppler echocardiography is inadequate. 
Class II
— Large volume aortic regurgitation with poor observation 
conditions by transthoracic Doppler echocardiography.
— Follow-up of progression of annuloaortic ectasia.
Class III
— Assessment of moderate aortic regurgitation with no 
symptoms or repercussion on the cavities or left ventricu-
lar function on transthoracic Doppler echocardiography.
Consensus indications for stress echocardiography in
organic left heart valve diseases 
Class I
— Low dose dobutamine Doppler echocardiography in 
aortic stenosis with low output (and small transvalvular 
gradient <30 mm Hg with left ventricular dysfunction)
— Exercise Doppler echocardiography to assess the tole-
rance of mitral stenosis and its repercussions on pulmo-
nary pressure when symptoms are difficult to assess or 
do not appear to be explained by the valve disease.
Class II
— Exercise Doppler echocardiography to assess the tole-
rance of organic mitral regurgitation, its severity and its 
repercussions on pulmonary pressure when symptoms 
are difficult to assess or do not appear to be explained 
by the valve disease.
Class III
— Exercise or Dobutamine Doppler echocardiography for 
routine assessment of organic mitral or aortic valve 
disease.
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Endocarditis on native valves 
The diagnostic criteria for infective endocarditis have recently
been modified [28] and Doppler echocardiography findings
have been included among in the major criteria (vegetations,
abscess, valve perforation, detachment of prosthesis, recent
regurgitation). The use of the new criteria improves the accu-
racy of the diagnosis of endocarditis [29]. The sensitivity of
transthoracic Doppler echocardiography to detect vegetations
is 50 to 60%. Transoesophageal echocardiography has
increased sensitivity (90 to 95%). When used together, the
specificity of these techniques is close to 100% [30].
Endocarditis on prosthetic valves
The incidence of endocarditis on prosthetic valves is 0.3 to
1.2%/patient year. Its’ complications carry a high mortality
[30 to 80% in early endocarditis; 20 to 40% in late forms [31-
32]], and are similar for mechanical prostheses and biopros-
theses.
Early diagnosis is essential. Doppler echocardiography is
currently the best investigation to visualise and measure
the size of vegetations, [33] and/or assess prosthetic dys-
function due to the endocarditis.
The diagnosis of endocarditis solely by transthoracic Dop-
pler echocardiography is difficult (acoustic shadow of the
prosthetic material). This limitation is resolved in part by
transoesophageal echocardiography, with a good sensitivity
and diagnostic accuracy as reported in the literature [34,
35]. The use of bi-and multi-plane probes undoubtedly
improves the sensitivity of the investigation [36]. However,
normal transoesophageal echocardiography does not for-
mally exclude the diagnosis of endocarditis on prosthesis
and the investigation should be repeated if suspicion per-
sists. The frequency of subsequent transoesophageal exa-
minations during follow-up is to be established considering
all clinical and laboratory parameters. Finally, transoeso-
phageal echocardiography is an essential investigation in
planning valve surgery and helps the choice of the best ope-
rative technique.
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VALVE PROSTHESES, 
VALVES REPAIR AND HOMOGRAFTS
When damage is incompatible with preserving the valve, the
treatment of the valve disease is replacement with a prosthe-
tic valve (approximately 9,000 cases per year in France). Two
main types of prostheses exist: mechanical prostheses (which
require long term anti-coagulation although their robustness
and longevity have been widely demonstrated [1, 2]) and bio-
logical prostheses (bioprostheses) which do not require any
specific treatment but have a shorter lifespan (average 10 to
15 years) because of risk of degeneration, which occurs faster
in people under 40 years [2, 3]. Aortic and mitral valve homo-
graft implantation is not widely used. In addition, whilst mitral
valve repair techniques are making rapid advances, aortic
valve repair techniques are not widely used in France.
Normal valve prostheses, 
valve repair and homografts
These display no abnormal clinical or radiological signs of dys-
function.
Initial assessment (2 or 3 months post-operatively)
Prosthetic valves
Each type of prosthesis has specific characteristics, represen-
ting a true echocardiographic and Doppler signature, which
depend on their haemodynamic profile, position and size. This
identity card is essential for patient follow-up.
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Baseline investigation
Each recipient of a prosthetic cardiac valve must have a base-
line assessment in order to record the haemodynamic cons-
tants for the type of prosthesis implanted [4-7]: this investiga-
tion should be performed when the patient has returned to a
stable haemodynamic situation (correction of anaemia, resto-
ration of normal heart rhythm etc.) i.e. generally within two
to three months after the procedure. The first month assess-
ment must not be used as the baseline record.
The following findings are recorded in the baseline report:
date of the procedure, type and size of prosthesis implanted,
heart rhythm, any associated procedures (bypass, tricuspid
annuloplasty, other valve replacement, preservation of the
mitral subvalvular apparatus). This report can be attached to
the document describing the features of the prosthesis and
given to the patient when discharged from the surgical depart-
ment.
As for a native valve disease, the echocardiographer must
assess left ventricular function in M-mode and two-dimensio-
nal mode, the size of the different cardiac cavities and the
pulmonary pressures when accessible to Doppler mode.
As for any valve disease, the echocardiographic assessment
of a prosthetic valve is based on a combination of anatomical
findings provided by M-mode and, particularly, two-dimensio-
nal imaging and Doppler haemodynamic findings. M-mode and
two-dimensional modes are of lower value for the anatomical
analysis of mechanical prostheses than for bioprostheses and
native valves because of the reverberations caused by the
metallic structures: the motion of the discs of bileaflet pros-
theses can, nevertheless, be clearly analysed in most patients
through the quality of current imaging. The morphology of the
leaflets of bioprostheses can also be clearly assessed by 2D
imaging [8]. The anatomical assessment is still therefore a
fundamental initial stage in the echocardiographic investiga-
tion of prosthetic valves.
The assessment of prostheses also uses Doppler examina-
tion. Regardless of type, any prosthesis causes a degree of
obstruction, which varies depending on its haemodynamic pro-
file, position and size: monitoring of the prosthesis and
patient follow-up are based on recording the transprosthetic
velocities by continuous Doppler.
Colour Doppler mode occasionally allows small para- or
intraprosthetic regurgitations from aortic prostheses to be
identified [9]. 
The essential parameters to be recorded to assess mitral
prostheses (table 1), which are analysed particularly from the
apical 4 chamber view are:.the mean transprosthetic gradient which is usually of
5±3 mmHg, and clearly abnormal when above 10 mmHg. It
is relatively independent of size of prosthesis, unlike aortic
prostheses but depends mostly on the type of valve (the
lowest gradients are seen with bioprostheses and bileaflet
prostheses and the highest with ball prostheses), heart
rate, rhythm and cardiac output..the “pressure half time” (PHT) as in the case of mitral ste-
nosis. This is a simple parameter to monitor prostheses
which reflects transprosthetic diastolic filling. Only the
uncorrected value of the PHT not adjusted for prosthetic
surface area is used. It should be remembered that calcula-
ting the prosthetic surface area from the PHT (Hatle equa-
tion: mitral area = 220/PHT) has only been validated for
mitral stenosis in native valves but not for normal prosthe-
tic valves. Only the PHT value should appear on the Doppler
echocardiography reports. PHT values are normally
between 70 and 100 msec: in atrial fibrillation it varies
greatly depending on the length of diastole. A PHT >150
msec is formally pathological..the functional surface area of the prosthesis by the
continuity equation, calculated in the same way as the
mitral surface area in mitral stenosis can be used if the
patient is in sinus rhythm and if no significant concomitant
aortic valve regurgitation is present. It varies from 1.6 to
2.8 cm2..the presence of intra or para-prosthetic regurgitations: con-
tinuous-wave Doppler must be used, because colour Dop-
pler is severely affected by reverberations from the pros-
thesis. The procedure follows in reverse to usual order,
identifying regurgitations first by continuous Doppler and
then localising them with colour Doppler. Intraprosthetic
regurgitations are common: 30 to 40% by TTE and in almost
100% of cases by TOE [10-15]. They are located at the junc-
tion between the mobile part and the metallic frame of the
prosthesis: their topography is therefore characteristic of
type of prosthesis. Para-prosthetic regurgitations are relati-
vely common during the immediate post-operative period,
are usually minimal and frequently disappear spontaneously
over a few weeks.
The main parameters to record for the analysis of aortic
prostheses (table 2), which are best seen in the apical 5
chamber and right parasternal views by TTE or suprasternally
in young people are:.the maximum and mean gradients: the mean gradient is
normally between 7 and 25 mmHg and is usually pathologi-
cal above 30 mmHg. It is useful to identify opening and clo-
sing clicks of the prosthesis for a better recording of the
transprosthetic flow. The mean gradient depends on the
type of prosthesis (lower gradients are found with biopros-
theses and bileaflet mechanical prostheses and higher
values for ball prostheses), size (number) +++ and cardiac
output..the functional or “effective” surface area of the prosthesis
by the continuity equation may be calculated in the same
way as for native valves if the patient is in sinus rhythm. For
outflow tract diameter, the diameter (or number) of the
prosthesis can be used. The prosthesis surface area ranges
from 0.9 to 2.2 cm2, depending on the type and calibre of
the prosthesis. As for aortic stenosis on native valves it is
also recommended that this surface be expressed as an
index to body surface area..the permeability index (PI), which is similar to the one
used for aortic stenosis, is a simple index, independent of
cardiac output and does not require measurement of the
left ventricular outflow tract diameter. The ratio of velo-
city time integrals or maximum velocities of the outflow
tract and transprosthetic flow can be used. In atrial
fibrillation it is essential to take into account the subaor-
tic flow and transprosthetic flow on the same cycle by
continuous Doppler. Normal PI values vary depending on
the type and diameter of prosthesis: they increase with
decreasing physiological obstruction from the prosthesis.
For mechanical valves the best index is seen with bilea-
flet prostheses: 0.41±0.12; for tilting disc prostheses the
PI is 0.33±0.06, and for ball prostheses it is 0.29±0.069.
The value is even higher for bioprostheses, especially
homografts: 0.56±0.10.
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.the presence of intra- or para-prosthetic regurgitations
which must always be investigated for by continuous,
pulsed and colour Doppler. [11-15].
High transprosthetic gradients and low prosthetic surface
areas can be seen in the absence of any dysfunction if the
prosthesis/patient size match is disproportionate (“mis-
match”): the indexed valve area should be >0.9−1 cm2/m2.
Mismatch is present if it is <0.85 cm2/m2 [13] and is severe
if the indexed surface area is <0.6 cm2/m2. Gradients may
also be elevated in high cardiac output. Conversely, with
low cardiac output, a low gradient can not exclude a pros-
thetic dysfunction.
However the finding of a high gradient and low prosthetic
surface area with Doppler is not synonymous with stenosis
of the prosthesis. “Falsely elevated” gradients can be seen
on Doppler. This gradient over-estimation phenomenon on
Doppler compared to the invasive haemodynamic gradient
is especially frequent with bileaflet mechanical aortic pros-
theses but is also possible with all types of prosthesis, inclu-
ding bioprostheses [14]. The problem is due to the diffe-
rence in gradient measurement site between Doppler and
haemodynamics and is explained by the pressure recovery
phenomenon. With bileaflet prostheses, Doppler records
localised high velocity flows in the central orifice of the
prosthesis whereas velocities are lower in the lateral orifi-
ces [16, 17]. In the absence of a baseline record, interpre-
tation of a high gradient on a mechanical aortic prosthesis
is impossible and requires more investigations such as by
radio-cinema of the prosthesis and, depending on clinical
context, transoesophageal echocardiography.
Apart from these specific problems which are now clearly
understood and are associated with the architecture and
small size of some prostheses there are considerable in vivo
and in vitro data to confirm the reliability of gradient and
surface area measurements as follow-up parameters for
prosthetic valves [18].
The use of systematic post-operative
transoesophageal echocardiography
Some publications have described early abnormalities
after mitral valve replacement [19]; they included non-
obstructive thrombi, fibrin strands, and more rarely obs-
tructive thrombi [20-23]. Physiological regurgitations are
not accessible to transthoracic echocardiography which
also fails to identify small para-prosthetic regurgitations
that are important to record for the patient follow-up in
the event of subsequent complications. Some authors have
therefore proposed systematic transoesophageal echocar-
diography during the months following mitral valve repla-
cement [19-23].
Conversely, there is no need to a systematic transoeso-
phageal echocardiography in the post-operative period
after isolated aortic valve replacement if not combined
with replacement of the ascending aorta.
Mitral and aortic repair, mitral and aortic homografts
Because of the complexity of these procedures a control
transoesophageal echocardiography is required in the ope-
rating theatre to confirm the quality of functional results
and to re-operate in the same procedure if a problem exists
in order to ensure an optimal result.
Patients who undergo a mitral or much less frequently
aortic repair or homograft insertion (aortic or more rarely
mitral) should undergo post-operative transthoracic Dop-
Table 1 Mitral prostheses: essential parameters to record.
Parameter Normal value Technical comments Diagnostic value
Mean gradient 5±3 mmHg
Pathological if >10 mmHg
Variable with rate, rhythm, output +++
Pressure Half Time (PHT) 70-100 msec
Pathological if >150 msec
Do not extrapolate for surface area +++
Regurgitations — Intraprosthetic
— Paraprosthetic
TOE > TTE ++
Table 2 Aortic prostheses: essential parameters to record.
Parameter Normal value Technical comments Diagnostic value
Mean gradient <30 mmHg Variable with type and size ++ of the prosthesis +++
Permeability index 0.23-0.66 Use the same cycle for 2 flows in AF by 
continuous Doppler
+++
Prosthesis surface area
Indexed prosthesis surface area 
0.9-2.2 cm2 If sinus rhythm ++
regurgitations — Intraprosthetic
— Paraprosthetic 
TTE > TOE  ++
Update of the French Society of Cardiology 267
pler echocardiography during the three months following
surgery to precise their valve statement, the existence of
any residual regurgitation and to investigate for a left intra-
ventricular obstruction due to post-operative anterior
mitral systolic movement following mitral valvuloplasty.
Follow-up beyond the 3rd month
Doppler echocardiography is the only truly reliable follow-
up investigation for prosthetic valves both in routine use
and in the event of dysfunction. In addition, in the absence
of dysfunction, the baseline Doppler haemodynamic assess-
ment of prosthetic valves is highly reproducible. As a result,
any changes in follow-up parameters found under similar
haemodynamic conditions, even if minimal, must be taken
into account in the subsequent follow-up [4].
Mechanical prostheses 
Once a baseline record has been obtained during the first 3
post-operative months, Doppler echocardiography follow-up
is indicated every 2 years in the absence of any new clinical
findings. This record should be compared with the post-ope-
rative findings and interpreted according to changes in left
ventricular function, heart rhythm and/or treatment. 
A three-monthly control of mechanical prostheses is man-
datory during pregnancy: this is justified by the increased
follow-up required because of changes in haemodynamics
and anti-coagulation modalities during pregnancy.
Mechanical prostheses are rarely implanted in the tricuspid
position because of their high thrombogenic potential: annual
Doppler echocardiography is appropriate in these cases.
Biological prostheses 
Follow-up every 2 years is appropriate in the absence of
any new clinical or laboratory event: because of the
potential degeneration specific to the bioprostheses, and
adverse haemodynamic changes after the 5th year of
implantation, annual follow-up is required beyond this
time [8]. The frequency of controls should be determined
Indications for transthoracic Doppler ultrasonography in
the initial assessment (first 3 months) of normal prosthe-
tic valves
Class I
—  Post-operative examination before discharge from 
hospital
— Reference examination within 3 months of surgery in 
patients considered as normal 
Indications for transoesophageal echocardiography in
the initial assessment (first 3 months) of normal pros-
thetic valves 
Class I
— Assessment of atrial arrhythmias when cardioversion is 
being considered in a non-anticoagulated or poorly anti-
coagulated patient.
— Suspected infectious endocarditis 
Class II
— Per-operative transoesophageal echocardiography in 
mitral valve replacement with conservation of the sub-
valvular apparatus. 
— Assessment after mitral valve replacement with a 
mechanical or biological prosthesis: investigation for 
para-prosthetic regurgitations, obstructive and/or non 
obstructive thrombi and/or strands, identification of 
physiological regurgitations.
— Assessment after aortic valve replacement combined 
with ascending aortic surgery or surgery for infectious 
endocarditis. 
— Atrial arrhythmias when cardioversion is being consi-
dered in a well anticoagulated patient.
Class III
Assessment after aortic valve replacement when trans-
thoracic Doppler echocardiography is normal.
Indications for Doppler echocardiography in the initial
assessment (first 3 months) of mitral and aortic repairs
and normal aortic and mitral homografts
Class I
— Per-operative transoesophageal echocardiography to 
guide the valve repair procedure.
— Per-operative transoesophageal echocardiography 
during mitral or aortic homograft insertion
— Baseline transthoracic Doppler echocardiography in 
the 3 months following mitral repair or homograft.
Class Il
— Transoesophageal echocardiography if the mechanism 
and/or quantification of possible residual mitral regurgi-
tation are not well identified by transthoracic Doppler 
echocardiography.
Indications for transthoracic Doppler echocardiography
in the follow-up (beyond 3 months) of normal mechani-
cal prostheses
Class I
— Control every 2 years, in the absence of any new clini-
cal or biological event.
— Control every 3 months during pregnancy because of 
physiological changes and changes in anti-coagulation 
modalities.
Class Il
— Annual control if patient is unable to correctly follow 
his/her anti-coagulation treatment.
Indications for transoesophageal echocardiography in
the follow-up (beyond 3 months) of normal mechanical
prostheses
Class III
— Transoesophageal echocardiography if transthoracic 
Doppler echocardiography is normal in a clinically stable 
patient
268 E. Abergel et al.
on an individual basis depending on the extent of dysfunc-
tion of the bioprosthesis until the time of reoperation.
Annual transthoracic Doppler echocardiography is man-
datory from the year of the procedure onwards if the
patient is under 40 years.
Valve repairs and homografts
A Doppler echocardiography control every 2 years is indi-
cated for mitral and aortic repairs with no significant resi-
dual regurgitations. If a moderate or severe residual
mitral or aortic leak is present, the situation is the same
as for the follow-up of moderate or severe mitral or aortic
regurgitation.
Aortic homografts are mostly indicated in young people
and in the treatment of endocarditis. The long-term out-
come of the latest generation of homografts is not yet
known [24]. The follow-up for aortic homografts can reaso-
nably be based on that of the aortic bioprostheses.
One elective indication for the mitral homografts is inability
to perform mitral valvuloplasty [25]. There are still too few
cases of these for their follow-up to be defined.
Complications of valve prosthesis, 
valve repair and homografts
These are suggested by signs of dysfunction (abnormal
murmur, arterial embolism, endocarditis, haemolysis).
Thrombo-embolic complications 
Obstructive prostheses thrombosis
The incidence of obstructive thromboses in prostheses
varies from 0.3 to 1.3 per 100 patient-years in the litera-
ture. The main factors responsible for thromboses are ina-
dequate anti-coagulation and the mitral localization. Bio-
prostheses are not free from this type of complication
[26], although thrombosis occurs mainly in mechanical pros-
theses. Despite recent advances in bio-compatibility and
haemodynamic profile all kinds of prostheses are likely to
thrombose.
If prosthesis thrombosis is clinically suspected, auscul-
tation may reveal anomalies (occurence of an abnormal
murmur, reduction in prosthetic sounds). Radio-cinema of
the prosthesis is particularly useful in this situation revea-
ling sometimes blockage or reduced motion of a mobile
part. Doppler echocardiography is the investigation of
choice to provide a reliable, rapid and inexpensive diagno-
sis [27, 28]..For mitral prostheses, transthoracic echocardiography
often allows the diagnosis to be made from the pre-
sence of reduced motion of the mobile part and occasio-
nally from direct visualisation of a thrombus. Colour
Doppler is also extremely valuable, showing frequently
an abnormal eccentric left ventricular filling jet. Conti-
nuous mode Doppler however has the most important
role, showing an obstructive haemodynamic profile with
elevated early diastolic velocity, elevated mean gra-
dient, prolongation of the PHT, reduction in functional
surface area if this can be calculated and appearance of
an intraprosthetic leak compared to the baseline trace
[5].
Whilst the positive diagnosis of obstruction is confirmed
by transthoracic Doppler echocardiography, the aetiolo-
gical diagnosis can only be made by transoesophageal
echocardiography [27-29]. Thrombosis of the prosthesis
must be distinguished from other causes of obstruction
such as an endocarditis vegetation, fibrous pannus
(these 2 situations are often difficult to distinguish), or
blockage of a cusp by the mitral subvalvular apparatus,
when it has been preserved [30]. .Thrombosis is a clinically rare situation with aortic pros-
theses. Diagnosis is based on CW-Doppler which shows a
rise of transthoracic gradients, a fall in the permeability
Indications for transthoracic Doppler echocardiography in
the follow-up (beyond 3 months) of biological prostheses
Class I
— Control every 2 years, in the absence of any new clini-
cal or biological event.
— Annual control from year 5 in the absence of any new 
clinical or biological event.
— Annual control in subjects under 40 years.
Class II
— Annual control in elderly patients and for biological 
prostheses less than 5 years.
Indications for transoesophageal echocardiography in
the follow-up (beyond 3 months) of biological prostheses
Class III
— Transoesophageal echocardiography if transthoracic 
Doppler echocardiography is normal in a clinically stable 
patient
Indications for transthoracic Doppler echocardiography
in the follow-up (beyond 3 months) of valve repairs and
homografts 
Class I
— Initial control at the end of the first year in the 
absence of any new clinical biological event.
— Control every 2 years in the absence of any new, clini-
cal or biological event.
Class II
— Systematic annual control in the absence of any new, 
clinical or biological event.
Indications for transoesophageal echocardiography in
the follow-up (beyond 3 months) of valve repairs and
homografts
Class III
— Transoesophageal echocardiography if transthoracic 
Doppler echocardiography is normal in a clinically stable 
patient
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index and a reduction in functional surface area. These
abnormalities are of great value if they can be compared
with previously normal results, which again highlights the
importance of having a baseline investigation. Transoe-
sophageal echocardiography is less effective than in
prosthetic mitral valve thrombosis: it can however assess
the movement of the mobile components and occasio-
nally directly visualise a thrombus. Radio-cinema of the
prosthesis must also be performed if the echocardiogra-
phy is equivocal. 
Non-obstructive prosthesis thrombosis and embolus
The annual risk of embolism in patients with prosthetic val-
ves varies depending on authors [26, 30] from 0.7 to 6 per
100 patient-years: the risk is high for mitral prostheses and
when concomitant atrial fibrillation is present. Cerebral or
peripheral embolism may occur in the context of obstruc-
tive prosthetic dysfunction but may also be seen in cases of
non-obstructive thrombosis, intra-atrial thrombosis [29] or
even endocarditis (septic embolus).
Non-obstructive thrombosis appears to be particularly
common in the immediate post-operative period when it
can be screened for by systematic transoesophageal echo-
cardiography. After the post-operative period, in the pre-
sence of peripheral embolism in a patient with a normally
functioning prosthetic valve at the tranthoracic echocardio-
gram, only multiplane transoesophageal echocardiography
can reveal non-obstructive thrombosis or left intra-atrial
thrombus [22, 29-31]. Transoesophageal echocardiography
also provides information about the size of the prosthesis
thrombus, a factor involved in the choice of treatment [32].
Bioprosthetic failure
More than 30% of bioprostheses require valve replacement
10 to 15 years after implantation.
This time is usually shorter in patients under 40 years and
with prostheses implanted in the mitral position [3]. Regar-
dless of the type of dysfunction, stenosis or regurgitation,
the diagnosis sometimes suggested by auscultation relies on
transthoracic Doppler echocardiography, which quantifies
the dysfunction and its haemodynamic repercussions. The
investigation is usually sufficient to provide all of the infor-
mation required for reoperation. Transoesophageal echo-
cardiography is only needed if the results of transthoracic
Doppler echocardiography are inconclusive or in specific
clinical situations (occurrence of or change of a pre-existing
murmur, fever, arterial embolism, congestive heart failure,
haemolysis).
Echocardiography generally shows morphological abnor-
malities of the prosthetic cusps which are thickened and
calcified and poorly mobile, occasionally with prolapse or
eversion of a cusp. Doppler may show chronic obstruction of
the prosthesis (with raised gradients, prolongation of the
PHT and reduced prosthetic surface areas) or moderate or
occasionally massive intraprosthetic leak in the event of
sudden rupture of a cusp.
Dehiscence of a prosthesis 
This is a serious complication which is particularly common
with repeated procedures which damage the valve annnuli
[33, 34]. It affects both bioprostheses and mechanical pros-
theses without distinction and may or may not be due to
infectious endocarditis.
In the aortic position, the diagnosis and quantification of
the leak are based on transthoracic Doppler echocardiogra-
phy. Transoesophageal echocardiography is indicated for
suspected endocarditis (examination for aortic wall abs-
cess), in the event of concomitant surgery on the ascending
Indications for transthoracic Doppler echocardiography
in thrombo-embolic complications
Class I
— Assessment of suspected or overt thrombosis of a pros-
thetic valve.
— Control after increasing anti-coagulation treatment or 
thrombolysis (the frequency of subsequent investigations 
should be determined on an individual case basis).
Indications for transoesophageal echocardiography in
thrombo-embolic complications 
Class I
— Assessment in clinically suspected prosthetic valve 
thrombosis as a systematic complement to transthoracic 
Doppler echocardiography, even if normal.
— Follow-up of a non-obstructive thrombosis remaining 
asymptomatic (the frequency of subsequent investiga-
tions should be determined on an individual basis)
Indications for transthoracic Doppler echocardiography
in structural valve deterioration (svd) of bioprostheses
Class I
— Diagnosis of SVD of bioprostheses suspected from the 
occurence of or change in a pre-existing murmur, appa-
rition of fever, arterial embolism, congestive heart 
failure or haemolysis.
— Follow-up of diagnosed SVD of a bioprosthesis (the 
frequency of subsequent investigations is guided by 
the quality of the initial results depending on the 
extent of bio-prosthesis dysfunction and its haemodyna-
mic consequences, until the time of reoperation).
Consensus indications for transoesophageal echocardio-
graphy in structural valve deterioration of bioprostheses 
Class I
— Assessment if transthoracic Doppler echocardiography 
does not provide the necessary information for a treat-
ment decision. 
Class II
— Assessment if transthoracic Doppler echocardiography 
does not identify the mechanism of the regurgitation (dege-
neration, dehiscence of the bioprosthesis and/or endo-
carditis). 
Class III
— Repeat investigation in the absence of a change in cli-
nical situation or haemodynamic parameters assessed by 
transthoracic Doppler echocardiography.
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aorta and if regurgitation increases over time. Some speci-
fic complications (aortic root abscess, perivalvular
damage,..) are sometimes difficult to asses by transthora-
cic Doppler echocardiography.
In the mitral position, para-prosthetic regurgitations can
be missed by transthoracic Doppler echocardiography
because of the acoustic shadow of the prosthesis. Diagnosis
and quantification of these para-prosthetic regurgitations
are then based on multiplane transoesophageal echocardio-
graphy [26, 33, 34].
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Class I
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the absence of any new clinical or laboratory findings 
(particularly indicators of haemolysis).
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transthoracic Doppler echocardiography .
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CHRONIC ISCHAEMIC HEART DISEASE
Transthoracic Doppler echocardiography (TTE) is the pre-
ferred tool for the diagnosis and follow-up of patients with
chronic ischaemic heart disease. TTE enables repeated
study of global and regional left ventricular systolic func-
tion, left ventricular remodelling and its consequences,
analysis of left ventricular filling and assessment of pulmo-
nary pressures. The investigation therefore provides consi-
derable useful information to adjust medical treatment,
monitor evolution and assess prognosis. Systematic control
of these parameters is useful in patients with abnormal left
ventricular systolic function even if no clinical changes
have occurred. Conversely, clinical symptoms guide the fre-
quency of Doppler echocardiography controls in patients
with good left ventricular function.
Resting Doppler echocardiography 
Left ventricular geometry and function (table 1)
Left ventricular morphology. 
Investigation for left intraventricular thrombus 
(cf acute coronary syndrome chapter)
The global morphology of the left ventricle is assessed by
two-dimensional echocardiography. Ventricular diameters
are measured systematically, in M-mode with long axis
parasternal or subcostal views. 
Global left ventricular remodelling can be assessed by
measuring volumes (Simpson biplane rule) and by measu-
ring the sphericity indices obtained in systole and diastole
(ratio of maximum length of the left ventricle to its width
in the apical view) [1-4].
Left ventricular aneurysm is characterised by deformity
of the diastolic outline in an akinetic or dyskinetic area
with a thin wall. The functional value of the residual normal
myocardium must be stated [5].
The investigation should always seek to identify a left intra-
ventricular thrombus. This is particularly common as a sequela
to anterior or apical infarction with an apical aneurysm [6]
(table 2).
Left ventricular systolic function
The assessment of regional left ventricular function involves
describing akinetic or hypokinetic areas in different views,
describing their extent, morphological features and segmen-
tal wall thickness. A thin (diastolic thickness <6 mm) and
dense appearance of akinetic myocardium indicates fibrous
scarring and is highly predictive of lack of viability [7].
Estimation of left ventricular ejection fraction (LVEF) by
two-dimensional echocardiography is part of the routine
investigation. The resting LVEF is the most important pro-
gnostic indicator in patients with chronic ischaemic heart
disease and plays an important role in treatment decisions,
including consideration for cardiac resynchronisation [8, 9].
Semi-quantitative visual assessment of the LVEF has the
major limitation of limited reproducibility, particularly for
low LVEF. LVEF is best measured by the modified Simpson
biplane method using harmonic imaging. This method also
has limitations in detecting the left ventricular endocar-
dium or left ventricular dilatation. Other techniques which
are not used routinely improve the repeatability and repro-
ducibility of measurements, such as the use of intravenous
contrast agents [10] or real time transthoracic three-
dimensional echocardiography, which has recently been
introduced [11].
Left ventricular filling pressures (table 3)
(cf recommendations on the echocardiographic
assessment of cardiomyopathies) 
Evaluation of diastolic function is essential. This enables fil-
ling pressures to be measured and provides prognostic
information. 
Transmitral flow analysis by pulsed Doppler is performed
routinely. An E wave deceleration time of <150 msec and/or
E/A ratio of >2 support raised left ventricular filling pressures
in the presence of left ventricular systolic dysfunction [12-16].
Other parameters need to be recorded if mitral flow is “nor-
mal” in appearance: Ea wave measurement by tissue Doppler
at the annulus with calculation of the E/Ea ratio; pulmonary
vein flow by pulsed Doppler (Ap-Am time); left ventricular
flow propagation during early filling by colour M-mode (Vp).
Functional mitral regurgitation 
Functional mitral regurgitation is often found in heart
failure. It is dynamic in nature and may increase or reduce
as a result of changes in left ventricular size, geometry and
load conditions. Left ventricular dilatation causes apical
and lateral displacement of the papillary muscles,
increasing the papillary muscle — valve annulus distance
[17]. Increased tension on the cordae is responsible for
valve restriction, apical displacement of the closure point
and reduced closure surface area resulting in an increase in
the surface area between the mitral cusps and the annulus
in mid-systole (area under the tent) and the height of the
closure point. These geometrical and contractile changes
cause imbalance between the traction and closure forces
on the mitral valve. During ventricular systole, the mitral
valve is subjected to two competing forces: closure forces
which are represented by left intraventricular pressure and
by systolic contraction of the annulus (reducing the annulus
surface area to be covered by the mitral cusps) and the
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traction forces which oppose the closure forces by restric-
ting valve movements in systole (and which occur as a
result of the force exerted on the mitral cusps by cordae
tendineae and by annulus dilatation) [17].
Increase in mitral regurgitation as a result of physical exer-
cise in patients with heart failure adds to restricting exercise
capacity and is associated with a poor prognosis [18-20]. These
dynamic changes are often accompanied by an increase in pul-
monary arterial systolic pressure and are associated with
changes in valve geometry and the dynamic nature of asyn-
chronism [21, 22].
Right cavities, pulmonary pressures 
and right ventricular filling pressures (table 4)
Analysis of the right cavities involves a morphological assess-
ment of the cavities, right ventricle and atrium, pulmonary
artery, superior vena cava and suprahepatic veins. Analysis of
right ventricular function is particularly useful following a
large right ventricular infarction. Right ventricular systolic and
diastolic functions are difficult to assess, requiring parameters
obtained using two-dimensional echocardiography to be com-
bined with Doppler flow measurements of pulmonary, tricus-
pid and suprahepatic vein regurgitation flows.
Pulmonary pressures can be measured from the tricuspid
regurgitation or pulmonary regurgitation flow (continuous
Doppler). 
Right atrial pressure (RAP) is defined either empirically
(generally 10 mmHg) or from the diameter of the inferior vena
cava (IVC) and its respiratory variations.
Transoesophageal echocardiography is not used routinely
but is useful to assess ischaemic mitral regurgitation.
Stress echocardiography (table 5)
Dobutamine echocardiography
One of the most widely used indications for this technique is
the investigation of myocardial viability by stress, particularly
dobutamine stress echocardiography although this is however
at the cost of increased ventricular arrhythmias if LVEF is <25%
[23]. Several types of response have been described as predic-
ting subsequent functional recovery: viability only in the pre-
sence of segmental resting asynergy with increase in contrac-
tility at low doses (protocol limited to low dose or load): a
biphasic response, representing an improvement in myocar-
dial thickening at low dose (or low load in the exercise test)
with secondary deterioration in the same territory in response
to high doses of dobutamine or high load in the exercise test:
and sustained improvement, defined as an improvement in
myocardial thickening at low dose or load maintained at high
doses or high loads. Documenting contractile reserve, even
though not synonymous with cell viability [24], predicts func-
tional recovery after revascularisation with good accuracy,
particularly if extensive (>4 segments) [25] and is also a risk
marker for cardiovascular events [26]. The optimum time to
reassess left ventricular function after revascularisation and
the methods for doing this (echocardiography or other imaging
methods) are debated. It appears however that functional
(and LVEF) reassessment are indicated beyond the 5th month,
improvement being seen up to 14 months after revascularisa-
tion in one third of cases [27].
Left ventricular diastolic wall thickness measured by MRI or
echocardiography [7] is an excellent predictive indicator for
functional myocardial recovery (sensitivity 94% and specificity
48%) after revascularisation. Diastolic thickness <6 mm exclu-
des viability with excellent diagnostic accuracy.
The meta-analysis published by Bax [28] compared the dia-
gnostic performance of different imaging methods. This was
based on 32 studies which used dobutamine echocardiogra-
phy, 53 isotopic studies and 20 studies which used positron
emission topography (with 18-fluorodeoxyglucose); 11 studies
directly compared dobutamine echocardiography with an iso-
topic technique. The overall sensitivity of low dose or high
dose of dobutamine infusion was 81%, with a specificity of 80%
and negative predictive value of 89%; for low dose dobutamine
echocardiography, sensitivity was 82%, specificity 79% and the
Table 1 Chronic ischaemic heart disease: main parameters to record to analyse left ventricular morphology and
function.
Parameters Thresholds/quantification Technical comments Value
Segmental 
Wall motion
Qualitative or semi quantitative 
scoring scale (cf table)
16 or 17 segment model 
(ASE) [1]
Prognostic value of WMSI
Describe the number of abnormal 
segments
Segmental kinetics score (WMSI) [1]
2 parasternal views,
3 apical view, sub-costal view 
Wall thickness >6-mm thick: preserved 
<6-mm: fibrous scaring [7]
Measured in M-mode (difficult) No reversibility if fibrous 
scaring (fibrosis)
Left ventricular 
ejection fraction
(LVEF)
Visual analysis (avoid) Limitation of visual 
estimation
Modified Simpson biplane method 
(disc summation method) [1]
Harmonic imaging 
Apical 4 and 2 cavity views 
Reference method 
Limitations:
— risk of under-
estimating volumes 
— limited to 2 planes 
(use of real time 3D)
ASE: American Society of Echocardiography; WMSI: Wall motion score index.
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negative predictive value 83%. For high dose dobutamine
echocardiography (investigation for biphasic response or sus-
tained improvement), the corresponding values were 79, 85
and 90%. For thallium myocardial scintigraphy with reinjec-
tion, the values were 88, 50 and 83% respectively and for posi-
tron emission tomography, 93%, 58% and 86% respectively.
This meta-analysis confirmed that the isotopic techniques are
significantly more sensitive than dobutamine echocardiogra-
phy although the echocardiography method has higher specifi-
city and negative predictive value (p<0.005). The impact of
documenting viability on indications for revascularisation and
prognosis were described in the meta-analysis by Allman [26].
This included 24 studies on a total of 3088 patients who were
examined by dobutamine echocardiography (n=7), thallium
myocardial scintigraphy (n=6) or positron emission tomogra-
phy (n=11). LVEF ranged between 25 and 31% and viability was
found in 42% of cases; 35% of patients underwent revasculari-
sation with an average follow-up period of 25 months. The
mortality rate was significantly lower in the group with viabi-
lity when revascularisation was performed (mortality rate
3.2%/year compared to 16%/year, p<0.0001, reduction in rela-
tive risk 79.6%). There was no significant difference in the
annual mortality rate in the patient group with no detected
viability (6.2 and 7.7%/year respectively). The annual morta-
lity rate in the group which underwent revascularisation was
3.2% with viability compared to 7.7%/year without viability.
This rose to 16%/year in the medically treated group with via-
bility compared to 6.2%/year without, highlighting the “loss of
Table 2 Chronic ischaemic heart disease: other essential parameters to record.
Parameters Thresholds/
quantification
Technical comments Value
Mitral regurgitation 
(MR)
State presence or absence of MR, 
even if mild and mechanism 
Colour Doppler, 
apical approach 
Threshold for significant MR:
ERO >20 mm2 [17]
Quantification by PISA or 
Doppler volumetric 
techniques 
Adverse prognostic value in 
the absence of pre-existing 
valve disease 
Investigation 
for thrombus
State dimensions and features 
(sessile or pedunculated)
Harmonic imaging
Apical views showing the apex
False positives and negatives 
diagnosis possible
Cardiac output Low output <2.2L/min/m2 left ventricular outflow tract 
output
Haemodynamic consequence
Pericardium Topography and volume if 
effusion 
Multiple views Signs of intolerance (cavity 
collapse, respiratory flow 
variations)
PISA: proximal isovelocity surface area; ERO: effective regurgitant orifice
Table 3 Chronic ischaemic heart disease: essential parameters to record to analyse left ventricular filling [12-16].
Parameters Thresholds/quantification Technical comments Value
Mitral flow (at valve tip) Type 1: relaxation abnormality 
(E/A <1 before 50 years old 
and <0.5 after 50 years old
Filling flow has multi-
factorial dependency 
(age)
If LVH absent suggests filling 
pressures not raised 
Type 2: pseudo normal Use other indices 
(E/Ea, E/Vp, Pulmonary 
venous flow)
Type 3: restrictive 
E/A >2 and/or EDT <150ms 
If LVEF reduced suggests 
raised filling pressures 
Tissue Doppler at annulus E/Ea <8 Suggests filling pressures 
not raised 
E/Ea >15 Suggests filling pressures 
raised 
In post infarction, indepen-
dent prognostic value (mor-
tality)
E: transmitral E wave; Ea: tissue Doppler E wave at annulus; LVEF: left ventricular ejection fraction; LVH: left ventricular hypertrophy; 
EDT: E wave deceleration time; Vp: colour M-mode propagation velocity. 
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Table 4 Chronic ischaemic heart disease: essential parameters to record for the right heart.
Parameters Thresholds/
quantification
Technical comments Value
RV kinetics and function RV wall kinetics 
RV dilatation (RV/LV diameter 
ratio >0.6) 
Parasternal (short axis) apical 
(4C) and subcostal views
Pulmonary ejection flow Pulmonary output Accelera-
tion time 
Calculation of resistances 
[31]
Pulmonary regurgitation 
Doppler flow
PHT and Vmin/Vmax of PR
PAPm and PAPd
Coupled Doppler 
and Pedoff probe
PHT (PR) <150 ms and/or 
Vmin/Vmax <0.5 supports 
raised RVEDP and prognostic 
value
Tricuspid regurgitation 
Doppler flow
TRVmax 
TR morphology (raised RAP)
PAPs
Pulmonary resistances 
Multiple views and Pedoff 
probe
Vmax >2.5 m/s (take account 
age, body surface area)
Inferior vena cava Diameter and respiratory 
variations 
Subcostal 2D and TM mode IVC collapse <50% in favor
 of raised RAP 
LV: left ventricle; RV: right ventricle; TR: tricuspid regurgitation; PR: pulmonary regurgitation; PAPs: systolic pulmonary arterial pres-
sure; PAPm: mean pulmonary arterial pressure; PAPd: diastolic pulmonary arterial pressure; PHT: pressure half time; RAP: right atrial 
pressure; RVEDP: RV end-diastolic pressure; Vmin: minimal velocity; Vmax: maximum velocity; ICV: inferior vena cava.
Table 5 Chronic ischaemic heart disease: optional parameters to record for the left heart.
Parameters Thresholds/
quantification
Technical comments Value
Left ventricular morphology
Sphericity index [4] L/l ratio [4] Repeated assessment for 
remodelling 
(treatment evaluation protocols)
The lower this ratio the 
closer the LV appears as a 
sphere. (normal L/l ratio = 2)
LV at end-diastole and endsys-
tole divided by the volume of a 
sphere of identical diameter to 
the long axis of the LV [4]
Left ventricular 
opacification with 
contrast agent [10]
Harmonic imaging
Specific settings for the 
contrast agent 
Apical 4 and 2 cavity views 
Precise measurement of volu-
mes and LVEF
(treatment evaluation protocols)
Improved detection of the 
endocardium and measure-
ment of volumes and LVEF 
[10]
Stress echocardiography
Dobutamine 
echocardiography
WMSI at different steps 
LVEF at different steps
E/Ea
PAPs
Investigation for myocardial
viability involving at least 
4 segments
Excellent predictive value for 
functional recovery 
(NYHA, LVEF) and prognosis 
No use for mitral regurgitation
Exercise 
echocardiography
Mitral regurgitation (ERO), 
RV
E/Ea
PAPs
Area under the tent 
Standard protocol, 
semi-seated on bicycle 
Zoom on PISA
TR (Vmax)
Prognostic value 
(resting ERO >20mm2
and Δ exercise ERO >13 mm2 
[20]
E: transmitral E wave; Ea: tissue Doppler E wave at annulus; LVEF: left ventricular ejection fraction; L: length of LV in 4C apical view; 
l: LV width in 4C apical view; PAPs: systolic pulmonary arterial pressure; PISA: proximal isovelocity surface area; ERO: effective regurgi-
tant orifice; RV: regurgitated volume; TR: tricuspid regurgitation; WMSI: wall motion score index
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chance” when a decision is taken not to revascularise in the
presence of viability; this decision may be taken as a result of
coronary anatomy and/or risk factors or co-morbidities.
Exercise echocardiography 
Exercise echocardiography has only been used to a limited
extent in the investigation of ischaemic left ventricular systo-
lic dysfunction. The two-dimensional imaging acquisition pro-
tocol is classical (resting, low load, high load, recovery, for
the 2 parasternal and 3 apical views) with additional Doppler
acquisitions of the proximal isovelocity surface area of the
mitral regurgitation jet (zoom on PISA), the transmitral flow
by pulsed Doppler at the annulus and tricuspid regurgitation
for measurements of pulmonary artery systolic pressure in the
different stages of the exercise test. The degree of mitral
regurgitation under baseline conditions does not correlate at
all with the changes in mitral regurgitation during exercise,
which vary greatly from one patient to the other [18]. An
increase in the volume of mitral regurgitation on exercise is
seen in almost 80% of cases. A large increase (increase in the
effective regurgitant orifice area or ERO >13 mm2) is seen in
almost 30% of cases. When mitral regurgitation is severe at
Consensus indications for Doppler-echocardiography in the diagnosis and follow-up of chronic ischaemic heart disease 
Class I
— Assessment of new symptoms or cardiovascular physical signs in a patient with known coronary artery disease.
— Assessment of recovery of left ventricular function after revascularisation 
— Repeated echocardiographical assessment of left ventricular function when results are useful to guide treatment. 
Class II
— Follow-up in the absence of signs of progression in treated coronary artery disease patients in order to screen for 
deterioration in left ventricular function.
Class III
— Systematic repeated echocardiography in the absence of a change in clinical state in patients without left ventricular 
systolic dysfunction.
Consensus indications for exercise or pharmacological stress Doppler-echocardiography in the follow-up of chronic
ischaemic heart disease
Class I
— Assessment for changes in symptoms suggesting progression of coronary artery lesions when the exercise test is:
• impossible to perform (orthopaedic problem, arterial disease, elderly patients, etc.);
• uninterpretable (left ventricular hypertrophy, left bundle branch block, etc.);
• negative submaximal and therefore inconclusive;
• equivocal (ST segment depression limited in time and amplitude).
— Detection of restenosis after coronary angioplasty when the exercise test is:
• impossible to perform (orthopaedic problem, arterial disease, elderly patients, etc.);
• uninterpretable (left ventricular hypertrophy, left bundle branch block, etc.);
• negative submaximal and therefore inconclusive;
• equivocal (ST segment depression limited in time and amplitude).
— Identification of the topography and/or extension of myocardial ischaemia to decide on possible myocardial revascu-
larisation.
— Investigation of myocardial viability in the presence of reduced left ventricular systolic function to guide the decision 
for revascularisation.
— Coronary risk stratification before non-cardiac surgery in intermediate or high risk patients.
Class II
— Exercise echocardiography to estimate the volume and tolerability (pulmonary pressures) of moderate resting mitral 
regurgitation. 
— Dobutamine echocardiography to investigate for myocardial viability in the presence of reduced left ventricular systo-
lic dysfunction to consider the indication for cardiac resynchronisation. 
Class III
— Follow-up of a stable coronary artery disease patient able to perform a maximum exercise test. 
— Repeated investigation in a stable coronary artery disease patient without other cardiovascular symptoms.
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rest (ERO ≥20 mm2), the incidence rises to 40% and when the
leak is moderate it is 25% [26, 28, 29]. The large increase in
regurgitated volume is usually accompanied by a significant
rise in systolic pulmonary artery pressure and a fall in cardiac
output [18]. Increased left ventricular asynchronism occurs in
20-30% of patients and is accompanied by an increase in the
severity of mitral regurgitation [21, 30].
The dynamic nature of functional mitral regurgitation has
prognostic implications, [18-20], the validated threshold being
an increase of ≥13 mm2 in the ERO during the exercise test. If
the increase in ERO exceeds this threshold the relative risk of
death is increased by a factor of 5 during a 3 year follow-up
period. Analysis of dynamic changes in ERO may inform the
effectiveness of medical treatments and guide therapy. 
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ACUTE CORONARY SYNDROMES
The acute coronary syndromes (ACS) are a group of various cli-
nical situations ranging from unstable angina to ST segment
elevation with myocardial infarction. Echocardiography provi-
des important information in the diagnostic and prognostic
assessment of ACS. The versatility of echocardiography instru-
ments into coronary care units and the development of porta-
ble echocardiography instruments make this technique the
non-invasive imaging method of choice for emergency use,
which is readily available and easy to repeat at the patient’s
bedside.
Conditions for performing the investigation
High quality echocardiography imaging including second har-
monic imaging is required in order to obtain a reliable assess-
ment of myocardial wall motion and thickening.
Transthoracic echocardiography (TTE) is sufficient in the
great majority of cases to provide diagnostic information and
screen for complications. Transoesophageal echocardiography
(TEE) is rarely indicated and is used above all if a complication
is suspected but is not sufficiently assessed by transthoracic
echocardiography. Transoesophageal echocardiography requi-
res a trained operator.
Diagnostic utility
Echocardiography may be a valuable aid if the diagnosis is
uncertain, particularly when there is a high index of clinical
suspicion of ACS with a normal or non-contributory ECG [1-3].
Echocardiography is generally not useful diagnostically in ACS
with ST segment elevation and must not delay the institution
of reperfusion techniques.
The development of portable echocardiography instru-
ments allows the diagnosis to be confirmed rapidly if neces-
sary by finding typical regional wall motion abnormalities and
to screen for some complications (pericardial effusion, LV
thrombosis, right ventricular extension of inferior wall myo-
cardial infarction, mechanical complications) [4].
The parameters to be recorded are predominantly regional
wall motion abnormalities. These must be examined systema-
tically in all views. Their topography closely reflects the coro-
nary vascular distribution in the absence of some anatomical
variations [5] (figures 1 and 2). The presence of akinesia or
severe hypokinesia in a vascular territory is a very sensitive
marker of ischaemia [6]. The investigation must be performed
using the ASE 16 segment (or 17 segment) classification [7].
The thickness of walls with wall motion abnormalities must
be reported. Normal wall thickness argues in favour of an ACS
being recent.
Echocardiography is highly sensitive (90-95%), to diagnose
ischaemia and infarction in patients with a high probability of
ACS [1-3]. It also has a high negative predictive value (approxi-
mately 95%). Diagnostic false negatives nevertheless occur in
non-Q wave infarction. If ACS is suspected and the ECG is non-
contributory the sensitivity of echocardiography to diagnose
ischaemia is highest if the investigation is performed during
pain, particularly if the wall motion abnormalities regress
after the ischaemia is treated. 
The positive predictive value of echocardiography to dia-
gnose infarction is lower depending on the likelihood of the
diagnosis of ACS being present. Echocardiography must not be
used in isolation to diagnose myocardial infarction. Segmental
wall motion abnormalities are not specific for infarction or
acute ischaemia and may represent post-ischaemic myocar-
dial dysfunction (stunning), infarction scar or non-ischaemic
segmental abnormalities such as acute myocarditis.
Echocardiographical assessment of myocardial
infarction (ACS with ST segment elevation)
All patients with an acute infarction (with or without ST seg-
ment elevation) should have an echocardiogram performed
during the hospital phase. In some patients the investigation is
performed on an emergency basis for diagnostic purposes, if
an infarction is complicated by cardiogenic shock or if a
mechanical complication is suspected. In uncomplicated
infarction, echocardiography is generally performed after
reperfusion treatments. Echocardiography must be performed
immediately if a patient develops sudden haemodynamic
deterioration. Patients with extensive wall motion abnormali-
ties on the initial echocardiogram are at higher risk of deve-
loping complications. Repeated echocardiographic follow-up
is indicated in these patients. 
Parameters to be recorded [7]
Segmental wall motion
Echocardiography should describe the severity and extent of
segmental wall motion abnormalities reporting the number of
abnormal segments in the different views, results of exami-
ning for segmental abnormalities in the different territories or
for signs of previous infarction with wall thinning (table 1).
The severity of the wall motion involvement must be reported
for each segment, taking into account myocardial thickness:
akinesia (no wall thickening or endocardial movement), hypo-
kinesia (reduced wall thickening and endocardial movement),
or dyskinesia (paradoxical systolic movement associated with
absence of wall thickening). 
The ischaemic area may be over-estimated as adjacent seg-
ments may experience stretching, stunning or load modifica-
tions effects. 
Left ventricular morphology
Left ventricular dimensions are usually measured in M-mode in
parasternal views. Left ventricular volumes (particularly the
end-systolic volume) are measured when the left ventricular
ejection fraction (LVEF) is measured using the Simpson
method in apical views. 
Particular attention should be paid to geometrical changes
of expansion of the infarcted area, remodelling or the esta-
blishment of an early left ventricular aneurysm.
Left ventricular systolic function
Left ventricular systolic function is assessed by measuring the
LVEF using the Simpson biplane method. A segmental wall
motion score index (WMSI) is calculated from the sum of the
abnormal myocardial segmental kinetics scores as the ratio to
278 E. Abergel et al.
the number of segments analysed also provides an estimate of
global systolic function. 
Diastolic function and left ventricular filling
pressures
The main parameters to record are transmitral flow by pulsed
Doppler, allowing measurement of the E and A wave and the
E/A ratio, E wave deceleration time (DT) and measurement of
the Ea wave by tissue Doppler at the mitral annulus, together
with calculation of the E/Ea ratio. If mitral flow is “normal” in
appearance, other parameters must be recorded such as ana-
lysis of pulmonary venous flow or lef ventricular flow propaga-
tion during early filling (Vp) by colour M-mode during two-
dimensional guidance. (table 2)
Left atrial size should be measured in an apical view (left
atrial surface area or volume as demonstrated in epidemiolo-
gical studies).
Right cavities, pulmonary pressures 
and right ventricular filling 
The size of the right cavities and right ventricular wall kinetics
must be assessed. Right ventricular injury should be examined
in inferior wall myocardial infarctions. Pulmonary pressures
can be calculated from tricuspid and pulmonary regurgitant
regurgitation flows. The diameter of the inferior vena cava
(IVC) and its respiratory variations must be measured.
Complications of myocardial infarction 
Acute mitral regurgitation 
Mitral regurgitation (MR) due to papillary muscle rupture is a
rare but serious complication of infarction generally resulting
clinically in cardiogenic shock. The posterior papillary muscle
is the most commonly affected. Papillary muscle rupture is
responsible for an eccentric MR jet due to segmental prolapse
which is occasionally difficult to assess by TTE colour Doppler
and is associated with a hyperkinetic left ventricle. TEE is
often required to confirm the diagnosis, frequently enabling
the ruptured papillary muscle to be visualised, particularly in
a transgastric view.
The prevalence of MR outside of possible papillary muscle
rupture ranges from 11% to 59% [8]. The main mechanism is
incomplete closure of the mitral valve with restriction of one
or both valves, often associated with widespread wall motion
abnormalities which may or may not involve the papillary mus-
cles. It is associated with a poor prognosis and increased risk
of mortality and heart failure independently of other prognos-
tic factors [9]. It is often clinically silent and must be exami-
ned systematically by echocardiography. Quantification of the
severity of mitral regurgitation is of prognostic importance.
Significant mitral regurgitation is defined by a surface area of
the effective regurgitant orifice (ERO) of >20 mm2 [9].
Septal rupture
The clinical presentation of septal rupture is similar to that of
papillary muscles ruptures. The echocardiographical diagnosis
is based on the finding of a septal discontinuity with more or
less well defined outlines, associated with an abnormal left to
right shunt between the ventricular cavities on colour 2
dimensional Doppler. If a large shunt is present, the left ven-
tricle is hyperkinetic, the left-to-right shunt Doppler flow is at
low velocity and the pulmonary pressures are raised. The site
of rupture depends on the topography of the myocardial
infarction. Interventricular communications from anterior
infarctions are best assessed using apical views. Interventricu-
lar communication from posterior wall myocardial infarctions,
which are occasionally associated with a right ventricular
myocardial infarction are best assessed by a short axis paras-
ternal and sub-costal view. TEE is only indicated in patients in
whom transthoracic echocardiography investigation is insuffi-
cient.
Left ventricular wall rupture
This is the most serious complication of infarction and gene-
rally results in rapidly fatal tamponade. The echocardiogra-
phical diagnosis generally only involves subacute ruptures.
Direct visualisation of the rupture is difficult and a Doppler
flow is rarely seen. The most highly suggestive echocardiogra-
phical sign is the presence of a smaller or larger pericardial
effusion which is heterogeneous in appearance and generally
circumferential [10].
Right ventricular myocardial wall infarction
Right ventricular extension occurs in 30 to 50% of cases of infe-
rior infarction [11]. Systematic ultrasound examination is
appropriate because of the poor specificity of clinical and
electrocardiographical signs and because of its prognostic
impact. The most common echocardiographical signs are seg-
mental wall motion or global right ventricular abnormalities
and right ventricular dilatation and dysfunction. Right Doppler
flow recording (pulmonary regurgitation) is useful for diagno-
sis and allows right ventricular filling pressures to be measured
[12]. (table 3)
Left ventricular remodelling, 
left ventricular aneurysm and thrombus
Wall expansion complicates extensive transmural infarctions
and results in thinning of the wall which may be complicated
by rupture or early left ventricular aneurysm formation.
Repeated echocardiography is useful to identify expansion of
the involved left ventricular myocardium. Left ventricular
aneurysm is seen on two-dimensional echocardiography as a
dyskinetic or akinetic thinner wall with deformity of the dias-
tolic volume. Aneurysm predisposes to intraventricular throm-
bus formation. Some echocardiographical features of the
thrombus (pedunculated and mobile) are associated with
increased risk of arterial embolism [13] (table 3).
True left ventricular aneurysm must be distinguished from
false ventricular aneurysm secondary to myocardial rupture
into partitioned myocardium. The false aneurysm has a nar-
row neck, an acute angle of attachment with the adjacent
myocardium and is characterized by a bi-directional Doppler
flow.
Pericardial effusion
A pericardial effusion may be seen with transmural myocardial
wall infarction, independently of myocardial rupture. Echo-
cardiography describes its size, distribution, tolerance and
progression.
Prognostic impact
Echocardiography provides prognostic information from an
assessment of the extent of the wall motion abnormalities,
left ventricular systolic and diastolic performance indices and
in screening for complications. 
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Table 1 Diagnosis and initial assessment of acute coronary syndromes: obligatory parameters to record for analysis of
left ventricular morphology and function. 
Parameters Thresholds/quantification Technical comments Value
Segmental wall motion Qualitative or semi-
quantitative scoring scale
(cf table 4)
16 or 17 segment model 
(ASE) [7]
Sensitive parameter
 for ischaemia
Limited specificity 
Describing the number of 
abnormal segments
Large number of views: 
2 parasternal views, 3 apical 
views, subcostal views 
Investigation for segmental 
abnormalities in separate 
territories or a sequella 
of old infarction with wall 
thickening 
Use analysis of wall 
thickness rather than 
analysis of displacement 
Regional wall motion Coronary vascular territories 16 or 17-segment model 
(ASE) [7]
Topographical value
Left ventricular 
ejection fraction (LVEF)
Visual analysis (avoid) Limitations of visual 
estimation
Modified biplane Simpson 
method (disc summation 
method)
Harmonic imaging
Apical 4 and 2-cavity views 
Reference method 
Limitations: 
— risk of under-estimating 
volumes 
— limited to 2 planes 
(utility of real time 3D)
— possible rapid change 
in LVEF post-infarction 
ASE: American Society of Echocardiography; LVEF: left ventricular ejection fraction.
Table 2 Diagnosis and initial assessment of acute coronary syndromes: obligatory parameters to record for analysis of
left ventricular filling pressures.
Parameters Thresholds/quantification Technical comments Value
Mitral flow
(at valve tip)
Type 1: relaxation abnormality 
(E/A <1 before 50 years old and 
<0.5 after 50 years old
Filling flow has multi-
factorial dependency 
(age, load conditions)
Suggestive of filling 
pressures not raised 
if no LVH
Type 2: pseudo normal Use other indices (E/Ea, 
E/Vp, Pulmonary venous 
flow)
Type 3: restrictive 
(E/A >2 or EDT <130-150ms)
Suggestive of filling pressu-
res if LVEF low
EDT ≤150ms has poor 
prognostic value [16]
Tissue Doppler
at annulus 
E/Ea <8 Suggestive of filling 
pressures not raised 
E/Ea >15 Suggestive of raised filling 
pressures 
Independent prognostic 
value for post-infarction 
death [18]
E: transmitral E wave; Ea: tissue Doppler E wave at annulus; LVEF: left ventricular ejection fraction; LVH: left ventricular hypertrophy; 
EDT: E wave deceleration time; Vp: Propagation velocity on colour M-mode.
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As wall motion abnormalities may improve after reperfusion
treatment, prognostic echocardiography can be performed
immediately before discharge from hospital.  
Several echocardiographical systolic and diastolic left ven-
tricular function parameters are of established prognostic
value. A raised segmental wall motion index (WMSI >2)
(table 4) or reduced left ventricular ejection fraction (LVEF
<40%) are associated with a high risk of death, heart failure and
ventricular arrhythmias [14]. End-systolic volume has a greater
prognostic value than LVEF [15]. Several diastolic function indi-
ces predict late left ventricular dilatation and death, such as a
shortened E wave deceleration time (<130-150 msec), restric-
tive mitral flow, an E/Ea ratio >15 by tissue Doppler on the
mitral annulus and left atrial dilatation [16-19]. The presence
of, even slight, mitral regurgitation, left ventricular remodel-
ling [9], or left ventricular aneurysm detected with repeated
echocardiography also has a poor prognosis.
A prognostic approach combining these different factors
has recently been proposed [20] (table 5). 
Other prognostic indices can be obtained with techniques
which are not used routinely. These include assessment of car-
diac cycle-dependent variation of integrated backscatter
Table 3 Diagnosis and initial assessment of acute coronary syndromes: other obligatory parameters to record. 
Parameters Thresholds/quantification Technical comments Value
Others 
Mitral regurgitation 
(MR)
State presence or absence of MR, 
even mild and mechanism 
Colour Doppler, apical view 
Threshold for significant MR: 
ERO>20 mm2 [9]
Quantification by PISA or 
Doppler volumetric techniques 
Adverse prognostic value in 
the absence of pre-existing 
valve disease 
Investigation 
for thrombus
State size and features 
(sessile or pedunculated)
Harmonic imaging
Apical views showing the apex
Possible diagnostic false 
positives and negatives 
Extension to RV RV wall motion abnormalities 
RV dilatation (ratio RV/LV 
diameter >0.6) 
Parasternal (short axis), apical 
(4C and right 2C) and subcostal 
views 
Doppler pulmonary 
regurgitation Doppler flow 
(PHT <150 ms, Vmin/Vmax <0.5)
Couple Doppler and Pedoff 
probe
Excellent diagnostic 
and prognostic value
Inferior vena cava Subcostal M-mode with 
respiratory trace 
Dimensions determined by 
blood volume and RAP
Pericardium Topography and volume of 
effusion 
Multiple views Signs of intolerance
(cavity collapse, respiratory 
flow variations)
PHT: pressure half time; RAP: right atrial pressure; Vmin: minimum pulmonary regurgitation velocity; Vmax: maximum pulmonary regur-
gitation velocity; ERO: effective regurgitant orifice area.
Table 4 Segmental wall motion score index (WMSI).
0 Hyperkinetic: Increased systolic wall thickening and endocardial movement
1 Normal: Normal systolic wall thickening and endocardial movement
2 Hypokinetic Reduced systolic wall thickening and endocardial movement
3 Akinetic No systolic endocardial wall thickening or movement 
4 Dyskinetic Paradoxical endocardial movement in systole with no systolic wall thickening 
Table 5 Multifactorial prognostic approach to coronary artery syndromes: [20].
Low risk Intermediate risk High risk 
LVEF 40% 30-39% <30%
Transmitral flow Abnormal relaxation Normal profile or abnormal relaxation Restrictive flow
Mitral regurgitation Absent or mild Moderate Severe
E/Ea <8 8-15 >15
PAPs <45 mm Hg 46-60 mm Hg >60 mm Hg
E: transmitral E wave; Ea: E wave by tissue Doppler annulus; LVEF: left ventricular ejection fraction; PAPs: systolic pulmonary arterial 
pressure.
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signal or the presence of a “no reflow” effect on myocardial
contrast echocardiography [21] or in transthoracic coronary
Doppler flow analysis [22].
Stress echocardiography
Acute coronary syndromes 
with ST-segment elevation 
Widespread use of primary angioplasty to treat the acute
coronary syndrome with ST segment elevation has changed
the investigation strategy for these patients. Dobutamine
echocardiography which was initially proposed to guide the
management of these patients is now prognostic useful and
quantifies the amount of stunned myocardium liable to reco-
ver in the weeks following recanalisation of the target coro-
nary artery [23].  
Transoesophageal echocardiography (mostly dobuta-
mine) is well tolerated and can be performed as early as
the 3rd day post MI (omitting the beta blocker on the day
of the investigation) in the absence of complications
during the acute phase [24]. This identifies areas of stun-
Table 6 Acute coronary syndromes: optional parameters to record. 
Parameters Thresholds/quantification Technical comments Value
Segmental wall motion 
score index (WMSI)
Different segmental scales Accuracy depends on number of 
analysable segments 
Reflects global left 
ventricular function
Prognostic index
Increasing WMSI [1] 
Normal WMSI =1
WMSI >2 predictive of post 
infarction LV dilatation [1]
Decreasing WMSI used in the 
TRACE study [14] 9 segments;
WMSI normal =2
(WMSI ≤1.2 equals LVEF ≤35%).
Prognostic value of 
repeated measurement of 
WMSI [14]
Colour M-mode
on mitral flow 
E/Vp≥1.5 predictive of 
in-hospital heart failure
Useful to identify pseudonormal 
mitral flow
Propagation velocity (Vp) 
measured on the first aliasing 
line (45 cm/s), from the mitral 
annulus to 4 cm into the LV 
cavity in early diastole
Limited reproducibility of 
measurement
LA volume Biplane area-length method
Normal value 22±6 mL/m2 
Adverse prognostic value 
if LA volume >32 mL/m2 
[19]
Stress echocardiography 
(dobutamine > effort)
(dipyridamole not used 
in France in this 
situation)
Low dose WMSI 
(5-15mcg/Kg/min)) for
contractile reserve and peak 
WMSI for ischaemia 
(and biphasic response)
Possible from day 3 post MI if no 
complications and beta blockers 
omitted on the same day 
No threshold value 
Importance of topography 
and extent of induced or 
modified segmental 
asynergy
E: transmitral E wave; LVEF: left ventricular ejection fraction; Vp: Propagation velocity in colour M-mode; WMSI: wall motion score index.
Table 7 Acute coronary syndromes: utility of new techniques, optional parameters to be recorded. 
Parameters Thresholds/quantification Technical comments Value
Myocardial contrast 
echocardiography [21]
Assessment of the area at risk 
Identification of “no reflow” 
phenomenon
Evaluation of viable myocardium
Intra-coronary contrast echocar-
diography validated, little used
Intravenous contrast echocar-
diography not used routinely 
Prognostic value from 
identifying the 
“no-reflow” phenomenon 
Transthoracic coronary 
Doppler [22]
Parameters suggestive of
“no reflow”:
— Diastolic flow deceleration 
time <185 msec
— Reverse systolic flow 
Recording LAD coronary flow by 
high frequency transthoracic 
Doppler 
Prognostic value from 
identifying the 
“no-reflow” phenomenon
Cardiac cycle-dependant 
variation of integrated 
backscatter
Non-invasive identifica-
tion of reperfusion 
Predictive of left ventri-
cular remodelling
LAD: left anterior descending artery 
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Figure 1. 16-segment classification (ASE) (adapted from 7).
Figure 2. Coronary vascular territories (adapted from 7).
Consensus indications for Doppler-echocardiography in the diagnosis and initial evaluation of acute coronary syndromes
(ACS) 
Class I
— Diagnosis of myocardial infarction or suspected ACS if diagnosis from classical criteria uncertain (ECG, cardiac enzy-
mes) including troponin.
— ACS and cardiogenic shock*
— Suspected mechanical complications of myocardial infarction*
— Investigation for right ventricular extension in the case of suggestive clinical signs in patients with an inferior myocar-
dial infarction. 
Class II
— Assessment of the extension of segmental abnormalities and left ventricular function during ischaemia.
Class III
— Diagnosis of myocardial infarction when the diagnosis is clear from classical criteria (ECG, cardiac enzymes)
* TEE indicated if TTE assessment inadequate. 
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ned myocardium by the infarction but viable with contrac-
tive reserve. It also detects residual ischaemia in the
infarcted or distant area (detecting multiple vessel
disease) [25-26]. Patients with contractile reserve have
significant increase in LVEF and a significant decrease of
segmental wall motion score index and end-systolic and
end-diastolic volumes [27].
The presence of myocardial viability is a powerful predictor
of the risk of cardiovascular complications. In the numerous
available publications [24,25,28], this test has an excellent
negative predictive value of around 90%, relative risk varying
between 2 and 5 depending on whether the end point used is
death ± recurrence of myocardial infarction ± recurrence of
myocardial ischaemia.
Dobutamine echocardiography compares favourably with
myocardial scintigraphy post-infarction: it has better specifi-
city although at the cost of poorer sensitivity [29].
Acute coronary syndromes without ST segment
elevation
Very little information is currently available on the use of
pharmacological stress echocardiography in this context [30,
31]. Lin [31], demonstrated that the feasibility and utility of
ECG was limited (ECG uninterpretable in 25% of patients and
of those who completed the exercise test, 38% did not achieve
the target heart rate) in a population of ACS patients assessed
after monitoring for 48 hours and followed up for an average
of 29 months. The presence of ischaemia on echocardiography
predicted events (death, infarction and subsequent revascula-
risation) in contrast to ischaemia on ECG. 
In the absence of electrical or enzymatic evidence of myo-
cardial ischaemia or myocyte necrosis a negative stress echo-
cardiogram should be reassuring and could avoid unnecessary
hospitalisations of patients at very low risk of cardiovascular
events.
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INDICATIONS FOR ECHOCARDIOGRAPHY 
IN CORONARY RISK STRATIFICATION
BEFORE NON-CARDIAC SURGERY
Cardiac complications are responsible for the main adverse
events following major surgery and detecting patients at high
risk of a per- or post-operative coronary event would seem
extremely useful. It is important before the procedure to
investigate for these as thoroughly as possible and thereafter
to monitor the patient at close intervals per and post-operati-
vely. Coronary risk was initially assessed in patients who had
undergone vascular surgery [1-4] because of the high preva-
lence of coronary artery lesions in this population. There are
many risk factors, involving clinical, electrocardiographical
and historical findings and also the type of surgical procedure
planned. This makes stratification difficult and requires a suc-
cessive stepwise assessment to be used.
Clinical risk markers have been established from large
series and are proposed in the North American recommenda-
tions (table 1) [5]. In order to facilitate clinical risk assess-
ment, some authors have proposed a simplified score which is
currently used by most teams (table 2). Clinical markers are
not however sufficient as the surgical procedure also influen-
ces the incidence of cardiovascular complications (table 1).
The first, clinical and electrocardiographical, stage is used to
detect patients at lower risk (patients with one or more minor
risk factors but no intermediate or major risk factors). If func-
tional capacity is good in this group (clinical evaluation and if
uncertain, exercise test), surgery can be proposed with no
other investigations (table 3). If the clinical assessment
detects factors suggesting high clinical risk the surgical proce-
dure should be postponed and a full cardiological assessment,
possibly combined with coronary angiography, should be
obtained. Patients at intermediary risk from the clinical fin-
dings in practice represent a large proportion (69% of patients
in a recent general surgical series) [6]. The management of
this group is still being debated and there is no single defini-
tion of the group. One definition often used is the presence or
1 or 2 intermediary clinical risk factors. Functional capacity
should be assessed first line with an exercise test which is use-
ful prognostically but its feasibility is often limited in an
elderly population with poor functional capacity [7, 8]. If
satisfactory and if the procedure is not high risk, surgery may
then be considered (possibly under beta blocker cover, see
below). If functional capacity is poor or unassessable or if the
surgery is intermediary or at high risk, a functional test is
appropriate (table 3). This is the situation in which stress
echocardiography (most often with dobutamine) has a role as
it is easy to perform and very widely studied in this type of
population.
Published studies on dobutamine echocardiography mostly
involve vascular surgery with an assessment of immediate
pre-operative and late prognosis. All of these indicate that the
investigation has excellent negative predictive value (97 to
100%) [1-4]. Development of a wall motion abnormality during
the test is however an independent predictive factor for per-
operative ischaemic events. The positive predictive value of
the investigation for serious events (death or infarction) is
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however relatively low (38% in the larger series) [9]. The heart
rate at which ischaemia develops (ischaemic threshold <70% of
MPHR) is an independent predictive factor for post-operative
events and can increase the positive predictive value of the
investigation to 53%. All patients who had a serious event (MI
or death) were in this group [9].
The prognostic value of stress echocardiography distant to
vascular surgery was confirmed by the same authors (10] in a
series of 316 patients followed up for 19±11 months. Two fac-
tors emerged as predictive of late cardiac events: a past his-
tory of MI (RR=3.8) and the extent of ischaemia in the pre-ope-
rative dobutamine echocardiogram (RR=6.5 when the number
of ischaemic segments was 3 or more).
These findings on the prognostic value of pre-operative
stress echocardiography have been confirmed before major
non-vascular surgery [6]. A dobutamine stress echocardiogra-
phy was performed in 530 patients unable to undergo an exer-
cise test prior to major non-vascular surgery in order to stra-
tify per-operative cardiac risk. This study confirmed that the
investigation had an excellent negative predictive value, all of
the cardiac events occurring in patients who had myocardial
ischaemia (NPV=100%). The positive predictive value of the
test was low (15%), although increased to 43% for a heart rate
ischaemic threshold of below 60% of MPHR, confirming the
results of Poldermans and co-workers [9] before vascular sur-
gery. There is at present no published work on the prognostic
value of stress echocardiography distant to major non-vascular
surgery.
Stress echocardiography and myocardial scintigraphy
have a similar diagnostic performance in screening for coro-
nary artery disease [11]. Many studies have been conducted in
pre-operative coronary risk assessment, mostly in candidates
for vascular surgery [12-14].
Meta-analyses of these studies have concluded either that
the two techniques performed similarly [15,16] or, more
recently, in a meta-analysis published by Kertaï et al. on 8119
patients [17] that stress echocardiography was statistically
significantly superior to myocardial scintigraphy, in particular
with a better positive predictive value for the development of
per-operative cardiac complications. Stress echocardiography
is therefore useful to assess and stratify pre-operative coro-
nary risk.
The role of stress echocardiography should be incorporated
into the perioperative therapeutic strategy for these
patients. 
Beta blockers are the cornerstone of treatment, producing
a significant reduction in the incidence of cardiac events both
per-operatively and late after the surgery. The first study,
published in 1999 [18], was a randomised prospective study of
the effect of a beta blocker (bisoprolol) versus placebo on
peroperative morbidity and mortality in major vascular sur-
gery in high risk patients with ischaemia in a pre-operative
stress echo. One hundred and seventy-three of 846 patients
with one or more risk factors had ischaemia in the stress echo.
Fifty-nine ultimately received bisoprolol and 53 the placebo
Table 1 Pre-operative clinical assessment.
1/ Clinical risk factors
— Major (high clinical risk)
• Acute or recent myocardial infarction (with residual 
ischaemia), unstable or severe angina
• Decompensated heart failure 
• Severe arrhythmias: High degree AVB, symptomatic 
ventricular arrhythmia, supra-ventricular arrhythmia 
with rapid heart rate 
• Severe heart valve disease.
— Intermediate (intermediate clinical risk)
• Stable angina
• Past history of myocardial infarction (clinical history 
or ECG Q wave).
• Stable heart failure
• Diabetes (particularly insulin-dependent)
• Renal insufficiency.
— Minor (low clinical risk)
• High age (over 70 years old)
• Abnormal ECG (LVH, LBBB, ST abnormalities).
• Non-sinus rhythm (generally AF)
• Reduced functional capacity 
• Past history of cerebrovascular accident 
• Poorly controlled hypertension.
2/ Type of surgery
— High cardiac risk (>5%)
• Surgical emergencies, particularly in the elderly 
• Aortic or major vascular surgery 
• Peripheral vascular surgery 
• Long procedures with bleeding risk
— Intermediate risk (1 to 5%)
• Carotid endarteriectomy 
• Head and neck surgery
• Orthopaedic surgery 
• Thoracic or intraperitoneal surgery
• Prostate surgery 
— Low risk (<1%)
• Endoscopies
• Superficial surgery
• Cataract surgery 
• Breast surgery. 
Table 2 Simplified clinical risk score before non-cardiac
surgery (from ref. 21).
Clinical risk markers:
Age ≥70 years
Current angina
Past history of myocardial infarction
Heart failure 
Treatment for ventricular arrhythmia 
Past history of ischaemic cerebral event
Diabetes
Renal insufficiency
Risk assessment:
Low clinical risk: no marker 
Intermediate clinical risk: 1 or 2 markers 
High clinical risk: 3 or more markers
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Table 3 Risk stratification algorithm before non-urgent, non-cardiac surgery.
Stage 1 Clinical risk assessment
Stage 2 Functional capacity (clinical evaluation +/– exercise test)
Stage 3 Level of risk of the intended surgical procedure
Good Poor
Low clinical risk (stage1) Intermediate clinical risk (stage 1)
(stage 1)
Low clinical risk (stage 1)
Low Intermediate High
Consider coronary angiography, or surgery on beta blockers.  
Low Intermediate
2 options
High
Surgery Functional test 
Negative test 
or limited ischaemia 
Early and/or  
extensive ischaemia
Postpone procedure + full 
cardiological assessment
Surgery  Intermediate 
clinical risk 
+  beta blockers
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(61 patients were excluded as they were already taking a beta
blocker or had early severe ischaemia). Two patients in the
beta blocker group (3.4%) and 18 patients in the placebo group
(34%, p<0.001) developed the combined criterion of either
cardiac death or non-fatal MI. The risk of peri-operative mor-
bidity-mortality was therefore reduced by a factor of 10 by
taking beta blocker treatment. The same patient population
was followed up for an average of 2 years after surgery and
the benefit of bisoprolol treatment was found to be maintai-
ned long term (12% cardiac events with bisoprolol compared
to 32% on placebo, p=0.025) [19]. The benefits of beta blocker
treatment (pre-operative IV Atenolol) had already been shown
[20] in patients with coronary artery disease or at risk of coro-
nary artery disease without documented ischaemia who were
undergoing non-cardiac surgery (vascular in 40% of cases).
The benefit in this situation was a significant reduction in total
mortality due to a reduction in cardiac deaths in the beta
blocker group which was seen within 6-8 months after surgery
and was maintained for 2 years. Work derived from the biso-
prolol study showed the limited utility of dobutamine echocar-
diography in patients who had only one or two clinical risk fac-
tors (table 2) and pre-operative beta blocker treatment [21].
The serious event rate in this group was low (0.8%) and the
test did not provide significant prognostic information. On the
other hand, patients with widespread ischaemia had a high
event rate (36%). In order to provide more information about
these findings the DECREASE II trial published by the same
group in 2006 was a randomised prospective trial of the role of
dobutamine echocardiography compared to systematic beta
blocker treatment in 770 patients with 1 or 2 clinical risk fac-
tors, awaiting vascular surgery [22]. The patients were rando-
mised between dobutamine echocardiography and systematic
beta blocker. Revascularisation was considered in patients in
the stress echo group who had widespread ischaemia (invol-
ving at least 5 segments). Beta blocker therapy was started if
limited ischaemia was found, in order to avoid the HR excee-
ding the ischaemic threshold. Finally, patients with a negative
test underwent surgery with no additional treatment. This
study showed that no strategy was superior to any other for
death or myocardial infarction (1.8 versus 2.3%). The authors
concluded that systematic beta blocker therapy could be used
to substitute for a functional investigation strategy in this
patient group, particularly as in their study, performing stress
echocardiography delayed surgery by approximately 3 weeks.
Several comments may be made about this conclusion. Firstly
the investigation delay varies greatly between centres: this
must be kept short in order not to expose the patient to exces-
sive risk. It is also important to consider the beta blocker
treatment protocol which began orally before surgery but
which notably was then switched to intravenous, with hourly
monitoring of the HR in order that it did not exceed 60 to
65/min. This was undoubtedly a crucial factor in obtaining the
observed efficacy although requires very close interval moni-
toring. Finally, it is important to remember that the finding of
ischaemia on stress echocardiography reduces the patient’s
medium term prognosis, independently of surgery. This must
be considered in the debate.
The second treatment which appears to be effective in
reducing the coronary risk is statins. An initial retrospective
study [23], in 2816 patients undergoing vascular surgery
showed statins to impact in hospital mortality. Fewer people
who were taking a statin died from a cardiovascular cause
than controls (8% versus 25%, p<0.001), with a relative risk of
operative mortality of 0.22 in patients taking the statin com-
pared to those who were not. The same authors demonstrated
the statins to be safe, with no increase in the risk of myopathy
[24]. Their potential utility was confirmed by another group
[25] in a retrospective study in patients undergoing non-car-
diac surgery. This study showed a significant reduction in total
hospital mortality in the patient group receiving a statin,
which was greater in patients at high cardiac risk. Prospective,
randomised studies are now required to validate the utility of
statin treatment in reducing perioperative coronary risk.
Coronary revascularisation prior to surgery has not yet
been shown to be useful in patients with coronary artery
disease. In the CARP study [26], 510 patients at increased car-
diovascular risk (clinical risk factors and/or ischaemia
demonstrated on scintigraphy) with documented coronary
artery disease were randomised into 2 groups: one group
revascularised before surgery and one group which was not
revascularised. The patients were awaiting vascular surgery
(33% for abdominal aortic aneurysm, 67% for lower limb arte-
rial disease). Coronary revascularisation was performed on a
non-randomised basis by bypass in 41% of cases and by angio-
Table 4 Echocardiographical parameters to be recorded during stress echo (exercise or dobutamine).
Parameter Threshold/quantification Technical comment Indication Prognostic value
Wall motion 
abnormality
— New abnormality 
— Or deterioration vs. rest
— Affecting at least 1 segment
Interpretation difficulty: 
inferobasal segment 
or postero-basal IVS
systematic — Excellent NPV
— Low PPV
(for vasc. or non-vascular surgery)
Extent of 
ischaemia
Number of ischaemic segments Difficulty when resting 
WM abnormality is
present
systematic — Probably reduced protective 
role of beta blockers 
— Number >3 predictive of 
increased post-operative risk (vasc)
Ischaemic 
threshold
— HR at which ischaemia 
develops 
— <60% MPHR 
(non-vasc. surgery)
— <70% MPHR (vasc. surgery)
Stop beta blocker 48h
before investigation
systematic — Per-operative prognostic value 
— No post-operative prognostic 
value 
NPV: negative predictive value, PPV: positive predictive value, HR: heart rate, MPHR: maximum predicted heart rate, 
IVS: interventricular septum, vasc: vascular.
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plasty in 59% of cases. Clinical features, beta blocker and sta-
tin use were identical in the two groups. The mortality rate
after a mean follow-up period of 2.7 years was 22% in the
revascularised group and 23% in the non-revascularised group
(p=0.92). The MI rate diagnosed from a rise in troponin in the
30 days following surgery was 12% in the revascularised group
and 14% in the non-revascularised group (p=0.37). This study
therefore appears to indicate that coronary revascularisation
before major vascular surgery is not beneficial in the short or
long term in stable coronary artery disease patients. This
result, however, should be interpreted with caution as this
was a study on an average population size with probable
recruitment bias: only 62% of the patients had had scintigra-
phy and only 74% were actually at increased cardiovascular
risk. Back and co-workers [27] had already shown that recent
coronary revascularisation (<5 years) by bypass or angioplasty
had no effect on the long term survival (5 years) in patients at
high cardiovascular risk awaiting vascular surgery. This crite-
rion however was only a secondary end point for the study,
limiting its value.
Conclusion: Stress echocardiography is a useful examina-
tion to stratify coronary risk in patients with clinical risk fac-
tors before surgery and has immediate and late prognostic
implications. It must include both the positive diagnosis of
myocardial ischaemia (development of WM abnormality) and
also its extent and the HR threshold at which the ischaemia
occurs (table 4). Beta blocker (and possibly statin) treatment
is useful in reducing morbidity and mortality before vascular
surgery. This must be widely used and can avoid the need for
functional tests when the procedure is to be performed shortly
and the patient is not at high risk. Coronary revascularisation
before surgery has not however been proven to be effective
and therefore should be considered on an individual case
basis.
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